[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 13979
1. Ruiz-Caro R, Veiga MD: In vitro Evaluation of Acyclovir/Chitosan Floating Systems. Materials (Basel); 2010 Dec 06;3(12):5195-5211

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chitosan (CS) floating lyophilized formulations (L) for gastric drug delivery of acyclovir (ACV) have been developed.
  • The results demonstrated that the freeze-drying process achieved effective floating systems capable of remaining within the stomach while the total amount of ACV is released from L.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AAPS PharmSciTech. 2005 Oct 19;6(3):E372-90 [16353995.001]
  • [Cites] Pharm Res. 1990 Jul;7(7):756-61 [2395805.001]
  • [Cites] Eur J Pharm Sci. 2008 Feb 5;33(2):166-76 [18248966.001]
  • [Cites] N Engl J Med. 1977 Jul 14;297(2):69-75 [194157.001]
  • [Cites] Pharm Res. 1990 Mar;7(3):299-303 [2339106.001]
  • [Cites] Ann N Y Acad Sci. 1977 Mar 4;284:49-59 [280147.001]
  • [Cites] Int J Pharm. 2008 Jan 22;347(1-2):39-44 [17662544.001]
  • [Cites] J Pharm Pharmacol. 1991 Jul;43(7):465-9 [1682458.001]
  • [Cites] Lancet. 2001 May 12;357(9267):1513-8 [11377626.001]
  • [Cites] Eur J Pharm Sci. 2007 Jan;30(1):1-6 [17101267.001]
  • [Cites] Eur J Pharm Biopharm. 2004 Jan;57(1):93-9 [14729084.001]
  • [Cites] Int J Pharm. 2004 Jun 11;277(1-2):141-53 [15158977.001]
  • [Cites] Eur J Pharm Sci. 2006 Jun;28(3):204-11 [16581235.001]
  • [Cites] Am J Med. 1982 Jul 20;73(1A):31-5 [7102710.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 May;81(10):3209-13 [6587347.001]
  • [Cites] Pharm Res. 1993 Feb;10(2):187-96 [8456064.001]
  • [Cites] J Am Coll Nutr. 2002 Oct;21(5):428-33 [12356785.001]
  • [Cites] Biosci Biotechnol Biochem. 2000 May;64(5):965-71 [10879465.001]
  • [Cites] J Pharm Sci. 2002 Dec;91(12):2593-8 [12434403.001]
  • [Cites] Int J Pharm. 2000 Oct 10;207(1-2):65-70 [11036231.001]
  • [Cites] Eur J Pharm Biopharm. 1998 Nov;46(3):285-91 [9885300.001]
  • [Cites] Eur J Pharm Biopharm. 1999 Sep;48(2):149-55 [10469933.001]
  • [Cites] J Control Release. 1998 Oct 30;55(1):3-12 [9795000.001]
  • [Cites] Br J Clin Pharmacol. 1986 Apr;21(4):459-62 [3707815.001]
  • [Cites] Biomaterials. 2008 May;29(14):2173-82 [18279951.001]
  • [Cites] Wound Repair Regen. 2008 May-Jun;16(3):425-31 [18471261.001]
  • [Cites] Eur J Pharm Biopharm. 2008 May;69(1):149-57 [18164931.001]
  • [Cites] N Engl J Med. 1986 Mar 20;314(12):749-57 [3005859.001]
  • [Cites] Drug Deliv. 2008 Jun;15(5):331-41 [18763164.001]
  • [Cites] J Pharm Sci. 1986 Mar;75(3):271-4 [3701609.001]
  • [Cites] Pharm Res. 1998 Sep;15(9):1326-31 [9755881.001]
  • [Cites] J Pharm Pharmacol. 2001 Aug;53(8):1047-67 [11518015.001]
  • [Cites] N Engl J Med. 1989 Feb 2;320(5):293-6 [2536136.001]
  • [Cites] Drug Dev Ind Pharm. 2000 Aug;26(8):857-66 [10900542.001]
  • [Cites] Colloids Surf B Biointerfaces. 2008 May 1;63(1):1-6 [18314312.001]
  • [Cites] Pharm Res. 1990 May;7(5):491-5 [1694990.001]
  • [Cites] N Engl J Med. 1986 Mar 13;314(11):686-91 [3005858.001]
  • [Cites] Int J Pharm. 2008 Apr 2;353(1-2):139-48 [18164151.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1999 Oct;47(10):1494-6 [10553646.001]
  • [Cites] J Pharm Sci. 2008 Sep;97(9):3820-9 [18186460.001]
  • [Cites] J Pharm Sci. 2007 Nov;96(11):3010-23 [17588259.001]
  • [Cites] Photochem Photobiol. 1996 Aug;64(2):242-5 [8760562.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Aug;47(8):2438-41 [12878501.001]
  • [Cites] Pharm Res. 1996 Nov;13(11):1668-72 [8956332.001]
  • [Cites] Drug Dev Ind Pharm. 2004 Apr;30(4):405-12 [15132183.001]
  • [Cites] Arzneimittelforschung. 1995 Apr;45(4):508-15 [7779152.001]
  • [Cites] AAPS PharmSciTech. 2007 Dec 14;8(4):E106 [18181527.001]
  • [Cites] J Control Release. 2004 Sep 14;99(1):15-26 [15342177.001]
  • [Cites] West J Med. 1997 Mar;166(3):211-5 [9143202.001]
  • (PMID = 28883376.001).
  • [ISSN] 1996-1944
  • [Journal-full-title] Materials (Basel, Switzerland)
  • [ISO-abbreviation] Materials (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Acyclovir / chitosan / controlled release / floating freeze-dried formulations / swelling behavior
  •  go-up   go-down


2. Palanivelu C, Rangarajan M, Parthasarathi R, Senthilkumar R: Laparoscopic resection for benign tumors of the stomach. JSLS; 2007 Jan-Mar;11(1):81-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic resection for benign tumors of the stomach.
  • BACKGROUND: Of all gastric tumors, less than 5% are benign.
  • The traditional treatment of symptomatic and some asymptomatic benign tumors has ranged from mucosal resection to limited gastrectomy.
  • Since the advent of laparoscopy, many different laparoscopic approaches to resection of benign gastric tumors have now been described in the literature.
  • METHODS: We reviewed our experience with laparoscopic approaches to surgical resection of 7 benign gastric tumors.
  • The tumor locations were the body (posterior wall), 3 cases; body (anterior wall), 1 case; lesser curvature, 1 case; fundus, 1 case, and antrum, 1 case.
  • Tumor size ranged from 2 cm to 6 cm in the greatest diameter.
  • There has been no tumor recurrence with a mean follow-up of 26 months.
  • DISCUSSION: Laparoscopic approach is slowly carving a niche for itself in the treatment of benign tumors of the stomach.
  • The basic principles are obtaining a precise preoperative pathological diagnosis; accurate tumor localization; achievement of tumor-free margins; avoidance of spillage of stomach contents, careful dissection of tumors in the esophagogastric junction, and preventing tumor seeding.
  • CONCLUSION: Based on ours and other studies, laparoscopic resection of benign gastric tumors is safe and feasible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Chir Hung. 1999;38(2):167-8 [10596322.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2004 Dec;14(6):344-8 [15599299.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):19-23 [10872521.001]
  • [Cites] Surg Endosc. 2000 Jun;14(6):524-6 [10890957.001]
  • [Cites] Surg Endosc. 2000 Aug;14(8):741-5 [10954821.001]
  • [Cites] Semin Laparosc Surg. 2001 Sep;8(3):189-94 [11588769.001]
  • [Cites] Surg Endosc. 2001 Aug;15(8):893-5 [11443418.001]
  • [Cites] Surg Endosc. 2001 Aug;15(8):896-7 [11443434.001]
  • [Cites] Surg Endosc. 2002 May;16(5):803-7 [11997826.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2003 Feb;13(1):37-40 [12676020.001]
  • [Cites] Ann Surg. 2004 Jan;239(1):22-7 [14685096.001]
  • [Cites] J Laparoendosc Surg. 1992 Dec;2(6):331-4 [1489999.001]
  • [Cites] Surg Endosc. 1994 Aug;8(8):887-9 [7992156.001]
  • [Cites] Surg Endosc. 1997 Mar;11(3):285-6 [9079612.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 1999 Feb;9(1):63-7 [10194695.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):2100-4 [10430405.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • (PMID = 17651562.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3015806
  •  go-up   go-down


3. Yao T, Utsunomiya T, Oya M, Nishiyama K, Tsuneyoshi M: Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features. World J Gastroenterol; 2006 Apr 28;12(16):2510-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features.
  • AIM: Minimal deviation carcinoma of the uterine cervix, otherwise known as extremely well-differentiated adenocarcinoma (EWDA), is characterized by its benign microscopic appearance in contrast to its aggressive behavior.
  • In order to elucidate the clinicopathological features and biological behavior of the gastric counterpart of EWDA, we, using immunohistochemistry, analyzed nine lesions for the phenotypic expression, proliferative activity, and the expression of oncogene-associated products.
  • METHODS: Clinicopathological features, including pre-operative biopsy diagnosis, were reviewed.
  • Using immunohistochemistry, Ki-67 labeling index and expression of p53 and c-erbB-2 protein in the gastric lesions were detected.
  • RESULT: Locations in the middle or upper third of the stomach and polypoid macroscopic features are characteristic of EWDA of the stomach.
  • All 9 cases of EWDA could be classified into gastric phenotype (5 lesions) and intestinal phenotype (4 lesions).
  • The former resembled gastric foveolar epithelium, mucous neck cells or pyloric glands, but their papillary structures were frequently elongated and the tumor cells and their nuclei were slightly larger and more hyperchromatic compared to normal epithelium.
  • CONCLUSION: Unlike minimal deviation carcinoma of the cervix, these findings suggest that EWDA of the stomach is a lesion of low-grade malignancy.
  • Because of its resemblance to normal gastric mucosa or mucosa with intestinal metaplasia, EWDA is often misdiagnosed.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Mucin-6. Mucins / analysis. Neprilysin / analysis. Phenotype. Receptor, ErbB-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1994 Apr;91(4):839-48 [7513368.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):511-7 [8129036.001]
  • [Cites] J Histochem Cytochem. 1996 Oct;44(10):1161-6 [8813081.001]
  • [Cites] Lab Invest. 1998 Mar;78(3):345-51 [9520947.001]
  • [Cites] Oncol Rep. 1998 Jul-Aug;5(4):867-70 [9625834.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1719-29 [10223565.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):104-6 [10393360.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):826-32 [10414502.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Hum Pathol. 2000 Mar;31(3):279-87 [10746668.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):713-8 [10854531.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):17-26 [11115563.001]
  • [Cites] Histopathology. 2000 Dec;37(6):513-22 [11122433.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):166-70 [11668493.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):80-6 [11823976.001]
  • [Cites] Hepatogastroenterology. 2002 May-Jun;49(45):869-73 [12064010.001]
  • [Cites] Am J Obstet Gynecol. 1975 Apr 1;121(7):971-5 [1115185.001]
  • [Cites] Br J Cancer. 1980 Feb;41(2):209-21 [6989383.001]
  • [Cites] Biochem J. 1980 Nov 1;191(2):645-8 [7016112.001]
  • [Cites] J Exp Med. 1981 Oct 1;154(4):1249-54 [6945392.001]
  • [Cites] Acta Pathol Jpn. 1983 Mar;33(2):395-401 [6869006.001]
  • [Cites] J Clin Pathol. 1985 Sep;38(9):1002-6 [2931454.001]
  • [Cites] Am J Surg Pathol. 1989 Sep;13(9):717-29 [2764221.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] Int J Cancer. 1991 Jan 21;47(2):304-10 [1988372.001]
  • [Cites] Int J Cancer. 1992 Apr 1;50(6):859-62 [1555884.001]
  • [Cites] Mod Pathol. 1992 Jul;5(4):384-90 [1353880.001]
  • [Cites] Cancer. 1992 Sep 1;70(5):1030-7 [1515980.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):558-62 [1520594.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):641-51 [7678777.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):589-93 [8439509.001]
  • [Cites] J Biol Chem. 1993 Mar 15;268(8):5879-85 [7680650.001]
  • [Cites] Gastroenterology. 1994 Jul;107(1):28-36 [8020672.001]
  • (PMID = 16688795.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / MUC6 protein, human; 0 / Mucin-6; 0 / Mucins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC4087982
  •  go-up   go-down


Advertisement
4. Yun M, Choi HS, Yoo E, Bong JK, Ryu YH, Lee JD: The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET. J Nucl Med; 2005 Jun;46(6):953-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET.
  • Physiologic (18)F-FDG uptake in the stomach can often cause false-positive results and lowers the usefulness of (18)F-FDG PET in evaluating the remnant stomach.
  • We assessed the role of gastric distension to see whether it is beneficial for the differentiation of recurrent tumors from physiologic (18)F-FDG uptake in the remnant stomach.
  • METHODS: Thirty patients (22 men and 8 women; age range, 27-80 y; mean age, 58.3 y) with a history of subtotal gastrectomy for gastric cancer underwent (18)F-FDG PET for various clinical indications.
  • After whole-body imaging, the patients were asked to drink water, and then spot imaging of the stomach was performed. (18)F-FDG uptake in the remnant stomach was considered positive for malignancy if it was persistently increased, whether focal or diffuse, after water ingestion.
  • We used 2 standardized uptake value (SUV) criteria to differentiate benign from malignant uptake.
  • First, a lesion was considered benign if its SUV was less than 2 on whole-body imaging.
  • Second, for a lesion with an SUV of 2 or above, it was classified as benign if SUV decreased by more than 10% after water ingestion.
  • When an SUV cutoff of 2 was applied for malignancy before water ingestion, all 17 patients with local recurrence were correctly identified, but 11 of the 13 patients without local recurrence were falsely considered to have a recurrent tumor in the remnant stomach.
  • CONCLUSION: Gastric distension by having patients drink a glass of water seems to be a simple, cost-effective way of improving the diagnostic accuracy of (18)F-FDG PET in patients with suspected recurrence in the remnant stomach.
  • Visual analysis with special attention to the configuration of (18)F-FDG activity after water ingestion seems to be more useful than the change in SUV in evaluating the remnant stomach.
  • [MeSH-major] Adenocarcinoma / diagnosis. Fluorodeoxyglucose F18. Gastric Stump / radionuclide imaging. Neoplasm Recurrence, Local / diagnosis. Radiopharmaceuticals. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. False Positive Reactions. Female. Fluorine Radioisotopes / pharmacokinetics. Gastrectomy. Humans. Male. Middle Aged. Positron-Emission Tomography. Whole-Body Counting

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937305.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


5. Kim JY, Whang JH, Zhou W, Shin J, Noh SM, Song IS, Kim JY, Lee SH, Kim J: The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation. Epigenetics; 2009 Jul 01;4(5):313-321

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The opposing influences of promoter methylation of VEGFR and increased VEGF expression concurrently influence Flt-1 and KDR expression in stomach cancer, colon cancer and hepatocellular carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001118.001).
  • [ISSN] 1559-2308
  • [Journal-full-title] Epigenetics
  • [ISO-abbreviation] Epigenetics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Brock KK, Sharpe MB, Dawson LA, Kim SM, Jaffray DA: Accuracy of finite element model-based multi-organ deformable image registration. Med Phys; 2005 Jun;32(6Part1):1647-1659

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For the abdominal cases, the liver, spleen, and external surface were explicitly deformed and the stomach and kidneys were implicitly deformed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2005 American Association of Physicists in Medicine.
  • (PMID = 28513963.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Bifurcations / Cancer / Clinical applications / Field emitters / Finite element methods / Finite-element and Galerkin methods / Hemodynamics / Image analysis / Image registration / Liver / Lungs / Materials properties / Mechanical and electrical properties of tissues and organs / Medical imaging / Pneumodyamics, respiration / biomechanics / biomedical MRI / finite element analysis / image registration / kidney / liver / lung / medical image processing / pneumodynamics
  •  go-up   go-down


7. Bates J: Is it me? Nurs Stand; 2007 Mar 14;21(27):28

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 'Are you going to put a tube down into my stomach?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27958949.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Yao HL, Yang ZL, Li YG: [Expression and significance of prostate stem cell antigen and Oct-4 in benign and malignant lesions of the stomach]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Jul;33(7):623-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of prostate stem cell antigen and Oct-4 in benign and malignant lesions of the stomach].
  • OBJECTIVE: To determine on the expression of prostate stem cell antigen (PCSA )and Oct-4 and detect their clinicopathological significance in benign and malignant lesions of the stomach.
  • METHODS: EnVision immunohistochemistry for assaying the expression of PSCA and Oct-4 was used in paraffin-embedded sections from specimens of primary foci (n = 58) and metastatic foci of regional lymph nodes (n = 36) of gastric cancer, peritumoral tissues (n = 20), and benign lesions of the stomach (n = 80).
  • RESULTS: The positive rates of PSCA and Oct-4 were significantly higher in gastric cancer than those in peritumoral tissues and benign lesions (P<0.05 or P<0.01).The positive cases of PSCA and Oct-4 in peritumoral tissues and benign lesions showed mild- to severe-atypical hyperplasia.
  • No difference of the positive rate of PSCA and Oct-4 was found between the primary foci and the metastatic foci of gastric cancer(P > 0.05).
  • The positive rates of PSCA and Oct-4 were significantly lower in infiltrating depth T(1) to approximately T(2), non-metastasis of lymph nodes, metastasis of lymph nodes N1 site, and non-metastasis of distant organs than those in infiltrating depth T(3) to approximately T(4), metastasis of lymph nodes, metastasis of lymph node N(2) to approximately N(3) site, and metastasis of distant organs(P < 0.05 or P < 0.01).Conclusion The expressive levels of PSCA and Oct-4 might be related to the invasive potential, metastasis of lymph nodes, and distant organs, it suggested the expressions levels of PSCA and Oct-4 might be important markers for reflecting the biological behaviors and prognosis of gastric cancer.
  • [MeSH-major] Biomarkers, Tumor. Membrane Glycoproteins / biosynthesis. Neoplasm Proteins / biosynthesis. Octamer Transcription Factor-3 / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Antigens, Neoplasm. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18667777.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / Octamer Transcription Factor-3; 0 / PSCA protein, human
  •  go-up   go-down


9. Allen D: Standard life. Nurs Stand; 2006 Aug 23;20(50):24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Dead bodies. Not usually a laughing matter, but I can barely suppress a titter when Silent Witness comes on the TV; every week someone with a serious expression upends the contents of a rubbery stomach into a dish and says thoughtfully: 'Hmm, last meal was a sausage. '

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27991169.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Leeper A: Starting out - Battling a stomach bug gives me an idea of how patients feel. Nurs Stand; 2006 Nov 22;21(11):25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Starting out - Battling a stomach bug gives me an idea of how patients feel.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001882.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Woodfield CA, Levine MS: The postoperative stomach. Eur J Radiol; 2005 Mar;53(3):341-52
Hazardous Substances Data Bank. Barium sulfate .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The postoperative stomach.
  • Gastric surgery may be performed for the treatment of a variety of benign and malignant diseases of the upper gastrointestinal tract, including peptic ulcers and gastric carcinoma.
  • Barium studies may also be obtained to evaluate for anastomotic strictures or ulcers, bile reflux gastritis, recurrent tumor, or other chronic complications during the late postoperative period.
  • Cross-sectional imaging studies such as CT are also helpful for detecting abscesses or other postoperative collections, recurrent or metastatic tumor, or less common complications such as afferent loop syndrome or gastrojejunal intussusception.
  • It is important for radiologists to be familiar not only with the radiographic findings associated with these various abnormalities but also with the normal appearances of the postoperative stomach on radiographic examinations, so that such appearances are not mistaken for pseudoleaks or other postoperative complications.
  • The purpose of this article is to describe the normal postsurgical anatomy after the most commonly performed operations (including partial gastrectomy, esophagogastrectomy and gastric pull-through, and total gastrectomy and esophagojejunostomy) and to review the acute and chronic complications, normal postoperative findings, and major abnormalities detected on radiographic examinations in these patients.
  • [MeSH-major] Postoperative Complications / radiography. Stomach Diseases / radiography. Stomach Diseases / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15741008.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 25BB7EKE2E / Barium Sulfate
  • [Number-of-references] 56
  •  go-up   go-down


12. Chaudry NU, Zafar S, Israr-ul-Haque: Benign nerve sheath tumor of stomach. J Coll Physicians Surg Pak; 2007 May;17(5):277-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign nerve sheath tumor of stomach.
  • Gastrointestinal mesenchymal tumors are a group of tumors, which originate from the mesenchymal stem cells of the gastrointestinal tract.
  • Gastric schwannoma is a very rare gastrointestinal mesenchymal tumor, which represents only 0.2% of all gastric tumors and 4% of all benign gastric neoplasms.
  • Endoscopic examination showed a round submucosal tumor with a central ulceration along the greater curvature of the stomach.
  • The pathological examination revealed a picture of spindle cell tumor.
  • Immunohistochemical stain was strongly positive for S-100 protein stain, and non-reactive for CD34, CD117, consistent with benign nerve sheath tumor of stomach i.e. gastric schwannoma.
  • [MeSH-major] Neurilemmoma / diagnosis. Neurilemmoma / surgery. Stomach Neoplasms / diagnosis. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17553326.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


13. Takahashi Y, Shimizu S, Ishida T, Aita K, Toida S, Fukusato T, Mori S: Plexiform angiomyxoid myofibroblastic tumor of the stomach. Am J Surg Pathol; 2007 May;31(5):724-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plexiform angiomyxoid myofibroblastic tumor of the stomach.
  • We report 2 cases of plexiform angiomyxoid myofibroblastic tumor of the stomach, a tumor entity that has not been described previously.
  • The tumor in case 2 was incidentally found at laparoscopic cholecystectomy.
  • Grossly, the tumors were 4.0 cm (case 1) and 4.5 cm (case 2) in their greatest dimension, and they were recognized as submucosal tumors.
  • The tumor caused gastric perforation in case 1.
  • Histologically, the tumors extended from the serosa to the submucosa of the gastric wall, showing a plexiform growth pattern.
  • Bland spindle tumor cells were observed, and they were separated by abundant intercellular myxoid matrix.
  • Immunohistochemically, the tumor cells were positive for alpha-smooth muscle actin and muscle actin, and negative for KIT, CD34, and S-100 protein.
  • Electron microscopic findings were consistent with the myofibroblastic nature of the tumor cells.
  • Although clinical follow-up data were insufficient, the histologic appearances suggested the benign nature of the tumors.
  • However, the tumor in case 1 caused gastric perforation and necessitated an emergency operation.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Myofibroma / pathology. Myxoma / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Cytoplasm / ultrastructure. Diagnosis, Differential. Disease-Free Survival. Gastrectomy. Humans. Immunohistochemistry. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2008 Dec;32(12):1910-2; author reply 1912-3 [18824895.001]
  • [CommentIn] Am J Surg Pathol. 2008 Dec;32(12):1910; author reply 1912-3 [18824897.001]
  • (PMID = 17460456.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Mohri T, Mohri Y, Ward DG, Wei W, Qi Y, Martin A, Kusunoki M, Johnson PJ: Discovery of a tumor-specific biomarker for gastric cancer using proteomic analysis in tissue and serum. J Clin Oncol; 2009 May 20;27(15_suppl):e15582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of a tumor-specific biomarker for gastric cancer using proteomic analysis in tissue and serum.
  • : e15582 Background: Gastric cancer is curable at an early stage.
  • METHODS: We explored surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to elucidate potential protein biomarkers of gastric cancer.
  • Twenty-one resected gastric cancer samples were compared with matched adjacent normal mucosa samples.
  • Serum from patients with gastric cancer (n=51) was compared with patients with benign gastric diseases (n=29).
  • RESULTS: Comparisons of surface-enhanced laser desorption /ionization time-of-flight mass spectrometry spectra of 21 gastric cancer tissue extracts with paired adjacent normal mucosa showed a total of 56 differentially expressed protein peaks (p<0.05; Wilcoxon test).
  • Twenty-two were up-regulated in gastric cancer tissue, whereas 34 were down-regulated.
  • The surface- enhanced laser desorption /ionization time-of-flight mass spectrometry spectra of serum contained 130 peaks, of which 67 were significantly associated with gastric cancer (p<0.05; Wilcoxon test).
  • We found five proteomic features (mass charge values of 2273, 3143, 3372, 3444, 3485) that were significantly up-regulated in both gastric cancer tissue and serum from gastric cancer patients.
  • The peak intensities of tumor-specific proteomic features were used to develop a linear regression model for calculating a diagnostic index.
  • CONCLUSIONS: Serum biomarker panels associated with tumor tissue are capable of distinguishing gastric cancer patients from non-cancer ones.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962357.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Xie L, Chen X, Qian X, Wei J, Ding Y, Zhang C, Liu B: Cell-free miR-10b and miR-21 as diagnostic biomarkers for malignant effusions. J Clin Oncol; 2009 May 20;27(15_suppl):11035

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11035 Background: Numerous studies have proved the roles of tissue microRNAs (miRNAs) as biomarkers in cancer diagnosis.
  • Cell-free miRNAs from plasma or serum have been shown to be good biomarkers in the diagnosis of cancers.
  • Here we tried to explore the potential application of cell-free miRNAs as diagnostic biomarkers to discriminate malignant effusions from benign.
  • METHODS: To obtain a molecular signature for malignant effusions, a stem-loop real-time PCR was adopted to measure the expression of 23 tumor-related miRNAs.
  • After a pre-screening for discarding low amount miRNAs in 10 samples (5 benign/5 malignant) and a proper internal control was identified, the expression levels of 7 miRNAs were further compared among 74 malignant effusion samples (35 gastric cancer-related ascites and 39 lung cancer-related plural effusions) and 30 benign effusions. miRNAs specifically associated with malignant effusions were derived from a training group (20 malignant/10 benign) and tested in a validation group (54 malignant/20 benign).
  • All samples were confirmed by both pathological and clinical diagnosis.
  • The expression of miR-10b was significantly different between benign and malignant effusions (P< 0.001).
  • CONCLUSIONS: In the present study, we demonstrated that cell-free miRNA can serve as a novel diagnostic biomarker in distinguishing malignant from benign effusions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964012.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Burzykowski T, Bang Y, GASTRIC project: Disease-free survival as a surrogate endpoint for overall survival in an adjuvant trial of curatively resected stomach cancer using individual patient data meta-analysis. J Clin Oncol; 2009 May 20;27(15_suppl):4517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease-free survival as a surrogate endpoint for overall survival in an adjuvant trial of curatively resected stomach cancer using individual patient data meta-analysis.
  • DFS is defined as recurrence of stomach cancer, all second cancers, or death from any cause.
  • We evaluated 3 year DFS as a surrogate for 5 year OS in adjuvant trials of stomach cancer by using individual-patient data (IPD) meta- analysis validation criteria.
  • METHODS: The GASTRIC group initiated an IPD meta-analysis of all randomized clinical trials comparing chemotherapy versus surgery alone for patients with curatively resected stomach cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962696.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hoque E, Karim S, Hossen M, Ahmed TU: Study to see the efficacy and toxicity profile of docetaxel-based chemotherapy in advanced stomach cancer in Bangladeshi patient population. J Clin Oncol; 2009 May 20;27(15_suppl):e15687

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study to see the efficacy and toxicity profile of docetaxel-based chemotherapy in advanced stomach cancer in Bangladeshi patient population.
  • : e15687 Background: Gastric cancer is the second most common cause of cancer death worldwide.
  • Advanced gastric cancer patients have a poor prognosis of 3 to 5 months.
  • Docetaxel has shown activity against gastric cancer as monotherapy and in combination with other agents.
  • The purpose of this study was to investigate the efficacy and toxicity profile of docetaxel based chemotherapy in advanced stomach cancer in Bangladeshi patient population.
  • METHODS: From January 2004 to December 2006, thirty patients with advanced inoperable gastric cancer (Gastric or esophagogastric adenocarcinoma) were included in the study.
  • The primary end point was time to tumour progression.
  • RESULTS: Among the 30 evaluable patients time to tumour progression was 11.5 months.
  • CONCLUSIONS: Adding docetaxel to CF regimen significantly improved time to tumour progression and survival rate in advanced gastric cancer patients.
  • Docetaxel in combination with Cisplatin and 5-fluorouracil is a very safe and active in patients of Bangladesh with advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962798.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Koucky K, Boxberger F, Albrecht H, Maennlein G, Wolff K, Ostermeier N, Schildberg C, Golcher H, Hohenberger W, Hahn EG, Wein A: Downsizing after palliative systemic chemotherapy with weekly high-dose 5-fluorouracil (5-FU) as a 24h-infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with metastatic adenocarcinomas of the stomach or the gastro-esophageal junction followed by secondary metastatic resection. J Clin Oncol; 2009 May 20;27(15_suppl):e15585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downsizing after palliative systemic chemotherapy with weekly high-dose 5-fluorouracil (5-FU) as a 24h-infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with metastatic adenocarcinomas of the stomach or the gastro-esophageal junction followed by secondary metastatic resection.
  • METHODS: 76 chemonaive patients (pts.) with histologically proven metastatic adenocarcinomas of the stomach or AEG tumours (tum.
  • ) (UICC IV), deemed to be non-resectable by the Interdisciplinary Tumour Board (ITB), were enrolled from 08/99 to 12/08.
  • This collective is presented here evidencing the efficacy of this interdisciplinary procedure in palliative (pall.) treatment of gastric cancer.
  • RESULTS: Last date of evaluation: Dec/31/2008; median age: 58,7 years; men/women: n=12/4; res. of the primary tum. prior to pall. chemoth.: yes/no: n=2/14, ECOG 0/1: n=5/11; primary tum. localisation: AEG tum.: n=7; gastric carcinoma: n=9, elevated CEA yes/no: n=5/11, elevated CA19-9 yes/no: n=5/11.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962360.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Chatterjee A, Bhattacharya S, Chatterjee AK, Biswas J, Mukhopadhyay B: A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers.
  • : 3050 Background: The prospective observational clinical study was conducted to know the efficacy of an alternative cancer treatment, 'psorinum therapy,' in treating liver, gall bladder, pancreatic, and stomach cancers.
  • The primary outcome measures of the study were (1) to assess the radiological tumor response;.
  • METHODS: The drug psorinum (an alcoholic extract of scabies, scrub, slough, and pus cells) was administered orally at 0.01ml-0.02 ml/Kg body weight as a single dose in empty stomach per day and ongoing to all the participants along with allopathic and homeopathic supportive cares.
  • RESULTS: 158 histopathology or cytopathology proved participants (42 of stomach, 40 of gallbladder, 44 of pancreas, and 32 of liver cancers) were included in the final analysis at the end of the study.
  • According to the RECIST criteria, complete tumor response occurred in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) cases.
  • CONCLUSIONS: Psorinum therapy is effective in treating stomach, gallbladder, pancreas, and liver cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Hohenberger P, Oladeji O, Licht T, Dimitrakopoulou-Strauss A, Jakob J, Pink D, Schwarzbach M, Ströbel P, Reichardt P, Wardelmann E: Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST). J Clin Oncol; 2009 May 20;27(15_suppl):10550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant imatinib and organ preservation in locally advanced gastrointestinal stromal tumors (GIST).
  • : 10550 Background: We assessed the outcome of patients with locally advanced gastrointestinal stromal tumors (GIST) undergoing preoperative therapy with imatinib.
  • METHODS: 36 patients with biopsy proven GIST (23 f, 13 m, median age 58 (27-85) yrs, 31 primary tumors, 5 local recurrences) of the esophagus/EGJ (n=5), stomach (n=17), duodenum (n=2), small bowel (n=3), or rectum (n=9) were treated with imatinib 400mg/d for 6 mos. preop.
  • Average tumor size was 10.5 cm (4-28 cm).
  • According to Consensus two tumors were low risk, 11 intermediate, and 23 were high risk for aggressive behaviour.
  • 33 pts. completed the treatment schedule, two died from unrelated disease, another one had to be operated for tumor rupture.
  • Of the remaining 33, median tumor size shrank to 55 mm.
  • Complete tumor removal was possible in 28 pts without operative mortality, but two pts showed previously undetected peritoneal spread (R2 resection).
  • The extent of resection found 5 of 6 inoperable pts now resectable and in 21/25 pts a less extensive procedure could be performed in comparison to recommendations by previous tumor boards (segmental gastric resection for gastrectomy, avoidance of pancreatectomy, transanal resection instead of colo-anal anastomosis).
  • Substantial tumor shrinkage facilitates radical but conservative surgery and results in organ-preservation in the overwhelming majority of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963946.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Emile François J, Brahimi S, Coindre J, Monges G, Scoazec JY, Blay J, Bouché O, Aegerter P: Molecular epidemiology of GISTs: Incidence of PDGFRA and KIT exon 9 mutations in the large French population-based study molecGIST. J Clin Oncol; 2009 May 20;27(15_suppl):10535

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10535 Background: KIT exon 11, KIT exon 9, and PDGFRA exon 18 mutations are present in 67%, 10% and 5% of gastrointestinal stromal tumors (GIST).
  • However most of these data are based on analyses of patients with overtly metastatic tumors.
  • METHODS: All patients leaving in France, whose diagnosis of GIST was achieved between June 1, 2006 and May 31, 2008 were includable in the study.
  • The median age at diagnosis 63.1 years (range [15-96]), and female/male ratio 0.98.
  • GIST originated in the stomach in 56.3% and small bowel in 29.3% of the cases.
  • Tumors were KIT+ in 90,4% of cases.
  • CD34 was expressed by more than 20% of tumor cells in 83.8% of gastric GIST and 39.7% of small bowel GIST respectively (P<0.0001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963887.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Conley AP, Araujo D, Ludwig J, Ravi V, Samuels BL, Choi H, Thall PF, Patel S, Benjamin R, Trent J: A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol; 2009 May 20;27(15_suppl):10563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).
  • The most common primary site of disease and metastasis was the stomach (29%) and liver (66%), respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963814.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Kang B Sr, Lee J, Ryu M, Im S, Park S, Kang W, Kim T, Oh D, Jung K, Kang Y: A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e21515

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors.
  • : e21515 Background: In our previous study, the presence of c-kit mutation as well as tumor size and mitotic count was an independent poor risk factor for relapse after curative resection of primary localized GIST.
  • METHODS: Patients who underwent complete resection of a primary GIST with 1) c-kit exon 11 mutation, and 2) ≥10 mitoses/50 HPF, or tumor size ≥10 cm, or ≥5 mitoses/50 HPF and tumor size ≥5 cm were eligible.
  • Stomach was the most common primary site (n=31).
  • Median primary tumor size was 7.5cm and median mitoses index was 12/50 HPF.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963446.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Buyse ME, Pignon J, GASTRIC: Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy and prognostic factors in gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy and prognostic factors in gastric cancer.
  • : 4539 Background: Despite potentially curative resection of stomach cancer, 50%-90% of patients die of disease relapse.
  • Our group has initiated an individual patient data (IPD)-based meta-analysis of all RCTs in the adjuvant gastric setting to quantify the potential benefit of S+CT over S, to study the role of various prognostic factors and their potential interactions with treatments.
  • Baselines variables included age, sex, tumour size (T) and stage, type of resection (D0, D1, D2 or more), performance status (PS) and geographic area.
  • CONCLUSIONS: Our interim results show a modest but significant OS benefit in favour of adjuvant CT and confirm the impact of tumour staging as well as age and PS on OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962986.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Wade FM, Pavlakis N, Receveur I, Leibman S, Smith GS: The role of cancer Nurse coordinator in foregut malignancy: Workload and costing considerations in the Australian setting. J Clin Oncol; 2009 May 20;27(15_suppl):e20559

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20559 Background: Foregut (esophageal and gastric) malignancy (FM) encompasses a number of diseases with poor outlook and complex and often morbid treatment.
  • Further, the CNC is pivotal in ensuring that benchmarks regarding intervals from diagnosis, to multidisciplinary assessment to treatment commencement are met.
  • The number of cancers arising from the esophagus or esophagogastric junction was 135 (62%), stomach 78 (36%) and small bowel 5 (2%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961033.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Sawaki A, Mizuno N, Takagi T, Hara K, Nakamura T, Tajika M, Kawai H, Matsumoto K, Kobayashi Y, Yamao K: Gastric submucosal tumors: Lessons learned from 10-year follow-up. J Clin Oncol; 2009 May 20;27(15_suppl):e15631

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric submucosal tumors: Lessons learned from 10-year follow-up.
  • : e15631 Background: Gastric Submucosal tumors (SMTs) were incidentally discovered esophagogastroduodenoscopy (EGD).
  • The aim of this study is to clarify the clinical features and long-term outcomes of gastric SMT at a single institute for 10-year period.
  • METHODS: We performed a total of 5307 EGDs and detected 188 gastric SMTs during 1998.
  • All clinical data including incidence, size and location in stomach were analyzed for the medical records.
  • RESULTS: Gastric SMTs were detected 188 (81 males, 107 females) of 5307 patients (3.5%).
  • 56% of SMTs located middle one third of stomach, and half (22%) of the remaining SMTs were detected at upper and lower one third, respectively.
  • Both of them underwent surgical resection and diagnosed as gastrointestinal stromal tumors (GIST).
  • CONCLUSIONS: The incidence of SMTs is 3.5%, majority (91%) is small (<2cm), and frequent location is middle one third of stomach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962746.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Koh Y, Kim H, Lee H, Lee K, Oh D, Kim J, Im S, Kim T, Kim W, Bang Y: KIT and PDGFRAmutation status and their immunohistochemical (IHC) expression profile of gastrointestinal stromal tumor (GIST) patients treated with imatinib (IMT): Seven-year single-center experience. J Clin Oncol; 2009 May 20;27(15_suppl):10558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT and PDGFRAmutation status and their immunohistochemical (IHC) expression profile of gastrointestinal stromal tumor (GIST) patients treated with imatinib (IMT): Seven-year single-center experience.
  • Tumor DNA was extracted to investigate the mutation status of KITexon 9, exon 11, PDGFRA exon 12 and 18.
  • Location of primary disease included stomach (33), small bowel (34), rectum (10), esophagus (1), and omentum/mesentery (7).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963944.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Kanzler S, Trarbach T, Seufferlein T, Kubicka S, Lordick F, Geissler M, Daum S, Galle PR, Moehler M, German Arbeitsgemeinschaft Internistische Onkologie (AIO): Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study.
  • : 4534 Background: Cetuximab has demonstrated high efficacy in combination with irinotecan-based therapies in metastatic colorectal cancer and irinotecan/folinic acid/5-FU (IF) may be an effective alternative to cisplatin-based regimens in advanced gastric cancer.
  • We therefore conducted a phase II AIO study to evaluate the tolerability and efficacy of cetuximab combined with IF as first-line treatment in patients with advanced gastric cancer.
  • METHODS: Patients (pts) were eligible with untreated adenocarcinoma of the stomach or oesophagogastric junction, with ECOG performance status (PS) < 2, measurable lesions and adequate organ functions.
  • Treatment was continued until tumor progression and tumor assessments were performed every 2nd cycle.
  • RESULTS: Between Aug 2006 and Sep 2007, 49 pts were enrolled: 71% were males, median age was 63 years (range 33-77), median PS was 0 (65% pts), and 69% of pts and 31% of pts had gastric and oesophagogastric junction carcinomas, respectively.
  • Among 48 response-evaluable pts, the overall response rate (CR + PR) was 42% (CR 4%/PR 38%) and the tumour control rate was 73%.
  • Cetuximab combined with chemotherapy in advanced or metastatic gastric cancer is under further investigation in an ongoing phase III trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962992.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Yoon J, Cho S, Bae W, Hwang J, Shim H, Chung I: Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer.
  • : e15599 Background: The role of the second line chemotherapy in advanced gastric cancer was not clear, but possibility of prolongation of survival is open question.
  • Irinotecan is promising agents in gastric cancer and this phase II study evaluated the efficacy and safety of combination chemotherapy with irinotecan, high dose of 5-fluorouracil (5-FU) and leucovorin in taxane and cisplatin based chemotherapy refractory metastatic gastric cancer.
  • METHODS: Eligible criteria were as followed; histologic confirmed adenocarcinoma of stomach, previously treated with taxane and cisplatin, age≥18, Eastern Clinical Oncology Group (ECOG) performance status of 1 or less, adequate organ function.
  • All patients were evaluable for safety and survival and twenty seven patients (79.4%) were evaluable for tumor response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Bogoevski D, Schurr PG, Koenig AM, Busch P, Kutup A, Izbicki JR: Is there still place for endoscopic mucosal resection in patients with early oesophageal carcinomas? J Clin Oncol; 2009 May 20;27(15_suppl):e15640

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • None of the 43 patients with high grade intraepithelial neoplasia (HGIEN) or oesophageal carcinoma limited to the mucosa had lymphatic spread, as compared with 15 of 68 (22.1%) with affection of the submucosa.
  • Multifocal neoplasia was detected in three patients with SCC HGIEN (30%) but not in AC HGIEN!
  • Nine out of 44 (20.4%) patients with early SCC had multifocal neoplasia, compared to 6 out of 53 (11.3%) patients in AC (p=0.322).
  • The sensitivity of the preoperative tumour dept staging (endoscopic ultra sound - EUS; and CT) was astonishing low (only 50% for cT1b), as was the specificity (66.7% for cT1a and only 87.5% for cT1b).
  • On multivariate analysis, only histological tumor type (AC) was independent predictor of survival.
  • A valuable alternative can be the limited resection of the oesophago-gastric junction under sparing of the healthy oesophagus and stomach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962740.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Bukhari MH, Byron E, Strosberg JR, Nasir NA, Henderson-Jackson E, Bui M, Hakam A, Domenico C, Kvols L, Nasir A: Primary gastroenteropancreatic poorly differentiated neuroendocrine carcinoma: Clinico-pathologic analysis of 68 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e15616

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15616 Background: Primary gastro-entero-pancreatic poorly differentiated neuroendocrine carcinomas (GEP-PDNECAs) are highly aggressive neoplasms with a very poor prognosis.
  • DATA SOURCES: Pathology archives, consultation files, tumor registry and social security index.
  • All available slides were reviewed and tumors were histologically sub-typed.
  • Sites: Colo-rectum 39, pancreas 19, small intestine (SI) 4, stomach 3, colon/SI/pancreas 3.
  • Of 68 tumors 37 (54%) were classified as small cell carcinoma (SCCA), 16 (24%) large cell carcinoma (LCCA), 5 (7%) mixed small and large cell (MSLCCA) and 10 (15%) poorly differentiated carcinoma with neuroendocrine features (PDCA-NEF).
  • Tumors were positive for chromogranin in 38/65 (55%), synaptophysin in 62/67 (92%), and CD56 in 17/21 (81%) cases.
  • CONCLUSIONS: Diagnosis of GEP-PDNECA can be based on histo-morphologic features and expression of neuroendocrine markers.
  • Synaptophysin was the most sensitive marker; however, a panel of 2 or 3 neuroendocrine markers (Syn, Cg and CD56) may be more useful to avoid under-diagnosis of GEP-PDNECA, especially in the metastatic setting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962728.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Macdonald JS, Benedetti J, Smalley S, Haller D, Hundahl S, Jessup J, Ajani J, Gunderson L, Goldman B, Martenson J: Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol; 2009 May 20;27(15_suppl):4515

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008).
  • : 4515 Background: INT0116 (SWOG 9008) was a prospectively randomized phase III trial of postoperative adjuvant therapy utilizing 5-FU/leucovorin plus external beam radiation in 582 eligible cases of resected stage IB-IV(M0) stomach and gastroesophageal junction cancers.
  • Subset analyses were performed for sex, race, T and N stage, D-level of surgical resection, tumor location (proximal or other), histology (intestinal or diffuse) and Maruyama index.
  • Thirty-five second tumors occurred in 31 cases.
  • Second tumors represented a spectrum of types of neoplasms commonly occurring in this age group (median age 60 years).
  • Excessive numbers of tumors known to be caused by radiation and/or chemotherapy were not noted.
  • More tumors may have occurred in the treated patients since their death rates were less than surgery only cases.
  • CONCLUSIONS: With >10 years median follow-up, survival remains improved in stage IB-IV (M0) gastric cancer cases treated with post-operative chemoradiaiton.
  • Women may be more likely to have diffuse histology gastric cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962700.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Jhawer M, Kindler HL, Wainberg Z, Ford J, Kunz P, Tang L, McCallum S, Kallender H, Shah MA, MET111643 Investigators and GlaxoSmithKline: Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study.
  • METHODS: Pts with distal esophagus, GE junction or stomach adenocarcinoma, 0-2 prior chemotherapy regimens, adequate organ function, measurable disease, and ECOG PS 0-2 are sequentially enrolled in 2 cohorts:.
  • Pre- and on-treatment tumor biopsies in select pts and plasma samples in all pts are analyzed for GSK089 effects on direct and downstream drug targets.
  • Single agent GSK089 demonstrates minimal antitumor activity in a cMET-unselected gastric population on the 5 on/9 off schedule.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962690.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Bose P, Thompson CL, Gandhi DG, Ghabach BS, Ozer H: Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib. J Clin Oncol; 2009 May 20;27(15_suppl):e19562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e19562 PBL are a group of highly aggressive neoplasms originally described in the oral cavity and jaws of HIV-infected patients.
  • They are terminally differentiated B-cell neoplasms, and typically lack common B-cell markers but uniformly express plasma cell markers.
  • EGD with biopsy revealed a high-grade PBL of the stomach.
  • The diagnosis was stage IVBE PBL.
  • However, studies of their immunophenotype and molecular histogenesis suggest that PBL are more closely related to plasma cell neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Aguiar Bujanda D, Bohn Sarmiento U, Saura Grau S, Rodriguez Franco C, Aguiar Morales J: Clinical activity of rituximab with either CHOP or CVP in MALT lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19530

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with gastric MALT lymphoma were included if resistant to or not eligible for anti-Helicobacter pylori therapy.
  • Primary origin: 14 stomach (64%), 3 skin, and 5 others (nodal, parotid gland, orbital, colon, and lung).
  • Patients with gastric lymphoma did not have bleeding or perforation during therapy.
  • Patients with gastric lymphoma (n=14) showed an ORR of 93% (CR 86%, PR 7%, SD 7%).
  • Radiation therapy was given as consolidation after chemotherapy to 3 patients with extra-gastric origin.
  • With a median follow-up of 28 months, two patients (gastric lymphoma) have relapsed at 4 and 12 months respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961030.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Cadoo KA, Lowery MA, Cumiskey J, McCaffrey J, Carney DN: Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract. J Clin Oncol; 2009 May 20;27(15_suppl):e19516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median age at diagnosis was 60 (15-83).
  • Primary sites of DLBCL were stomach 35 (67%), small bowel 11 (21%) & colon 6 (12%).
  • 39 (62%) patients underwent surgery at diagnosis due to acute presentation with perforation, bleeding or obstruction, or to obtain histology.
  • Following confirmed diagnosis, 61 patients received anthracycline based chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960953.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Boers JE, Meeuwissen H, Methorst N: HER2 status in 146 gastroesophageal carcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridisation methods (FISH and SISH). J Clin Oncol; 2009 May 20;27(15_suppl):e15555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15555 Background: In the industrialized world, the incidence of adenocarcinomas of the distal esophagus/gastric cardia is increasing rapidly and though the incidence of carcinomas of the gastric body / antrum are decreasing they still represent a significant health problem.
  • A large phase III trial in which HER2-positive gastric cancer patients are treated with trastuzumab is ongoing.
  • RESULTS: IHC was carried out on biopsies of 146 patients with adenocarcinomas of the esophagus (n=44), gastric cardia (n=28), body (n=24) and antrum (n=50).
  • Heterogenous HER2- positivity with partial staining/amplification was present in 73% of the adenocarcinomas, occasionally with only a tumor area of 10-20% showing positivity.
  • HER2-amplification was present in 27% of esophageal and 18% in gastric cardia carcinomas (resulting in 24% amplification of tumors of the esophago-gastric region).
  • In the distal stomach, 7% HER2-amplification was seen.
  • CONCLUSIONS: HER2 amplification is present in a significant proportion of esophago-gastric region adenocarcinomas (24%) but at a much lower rate in the distal stomach (7%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962336.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Haid A, Knauer M, Köberle-Wührer R, Wenzl E: Sentinel node biopsy in breast cancer: technique and indication. Wien Klin Wochenschr; 2005 Feb;117(4):121-128

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Sentinel node biopsy (SNB) has proved to be a useful and accurate procedure for lymph node staging in breast cancer and melanoma and should be standard of care in the treatment of these tumors.
  • In other malignancies (colon, rectum, stomach, esophagus, head and neck and thyroid, cervix uteri) it is still under investigation.
  • Accepted indications are uni- and multifocal tumors smaller than 3 cm without suspicious findings in the axilla, furthermore SNB is indicated in patients with large ductal carcinoma in situ (>2 cm) and/or with assumed microinvasion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28108807.001).
  • [ISSN] 1613-7671
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Keywords] NOTNLM ; Breast cancer / Indications / Sentinel node biopsy / Technique
  •  go-up   go-down


39. Limentani SA, Awada A, Dirix L, Beck J, Dieras V, Binlich F, Germa C, Agrapart V, Powell C, Hershman D: Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in patients with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e14554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in patients with solid tumors.
  • In this phase 1 study, a combination dose of neratinib plus vinorelbine that is tolerable was determined in patients (pts) with solid tumors.
  • Tumor measurements were made every 6 wks by modified RECIST criteria.
  • Preliminary efficacy data show that 1 pt with stomach cancer had stable disease, lasting ≥21 weeks.
  • CONCLUSIONS: The combination of 240 mg neratinib and 25 mg/m<sup>2</sup> vinorelbine was found to be tolerable and to demonstrate early evidence of clinical benefit in pts with solid tumors, to be assessed further in pts with metastatic ErbB-2+ breast cancer in part 2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963588.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Pozzo C, Ohashi Y, GASTRIC project: Meta-analyses of randomized trials assessing the influence of chemotherapy and prognostic factor in advanced/recurrent gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4550

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analyses of randomized trials assessing the influence of chemotherapy and prognostic factor in advanced/recurrent gastric cancer.
  • : 4550 Background: Advanced or recurrent stomach cancer remains an incurable disease.
  • The GASTRIC project is an individual-patient-data (IPD) based meta-analysis in the advanced disease setting to quantify the potential benefit of various chemotherapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963035.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Stella G, Rojas Llimpe F, Barone C, Falcone A, Di Fabio F, Martoni A, Lamba S, Ceccarelli C, Siena S, Bardelli A, Pinto C: KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e15503

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients.
  • : e15503 Background: The prognosis of advanced gastric cancer (GC) patients (pt) is still poor despite the introduction of new chemotherapy regimens.
  • METHODS: We have collected 44 tumor samples from pts affected by locally advanced or metastatic GC undergoing cetuximab combination therapy as first-line treatment in two consecutive phase II studies.
  • Genomic DNA was extracted from paraffin-embedded tumor specimens from all cases.
  • RESULTS: KRAS and BRAF mutations were detected in 5 (11.4%) and 1 (2.3%), respectively, of the 44 tumors analyzed.
  • One case had the A11V variant that had been reported in hematopoietic and lymphoid tissue of the stomach.
  • As a whole, 13.6 % of the analyzed tumors carried a mutation in either KRAS or BRAF genes.
  • In our cases, the mutational status of KRAS and BRAF genes does not correlate with the response to cetuximab-based therapy in advanced gastric cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962223.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Lustberg MB, Nuovo J, Thomas JP, Monk PJ 3rd, Kim S, Villalona-Calero M, Bekaii-Saab T: Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study. J Clin Oncol; 2009 May 20;27(15_suppl):2569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study.
  • The beneficial interactions of paclitaxel and carboplatin in upregulation of TP promise to make capecitabine more tumor specific and to provide the expected synergy.
  • METHODS: Patients with advanced solid tumors received carboplatin on day 1, paclitaxel on days 1, 8, 15 and capecitabine orally twice a day on days 8-21, every 4 weeks.
  • There were 10 confirmed responses [4 CR (esophagus, stomach, unknown primary and ampullary); 6 PRs (Pancreas (3), unknown primary, anal and esophagus] and stabilization of disease > 3 months in 12 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961879.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Morales D, Beltran B, Hurtado de Mendoza F, Riva L, Quiñones P: Analysis of prognostic factors in patients with EBV positive diffuse large B cell lymphoma of the elderly. J Clin Oncol; 2009 May 20;27(15_suppl):e19542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extranodal disease occurred in 6/11 (54%) patients: pleura (n=2), suprarenal gland (n=1), stomach (n=1), cecum (n=1), bone (1), skin (1) and bone marrow (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960995.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Servarayan CM, Chandramohan A, Datta D, Manickavasagam K: p53 and its influence in adenocarcinoma stomach. J Clin Oncol; 2009 May 20;27(15_suppl):e15685

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and its influence in adenocarcinoma stomach.
  • : e15685 Background: Gastric cancer is the second most common cause of the malignancy in the world after lung cancer.
  • METHODS: This is a immunohistochemical prospective experiment study done on 76 cases of Gastric Adenocarcinoma.The location of the tumors were recorded as in the proximal stomach (fundus and body) and distal stomach (antrum, prepylorus, and pylorus).
  • 33 out of 60 (55%)of the males and 8 out of 16 (50%) females were reported of having gastric adenocarcinoma with p53expression.
  • The histology of the tissue samples from the gastric adenocarcinoma patients had following relationship with the p53 immunoreactivity, 20 out of 37 cases(54.05%) of the well differentiated,7 out of 17 cases (41.18% )of the moderately differentiated, and and 13 out of 21 cases(61.90%) of the poorly differentiated gastric adenocarcinoma showed positive immunoreactivity.
  • 15 out of 33 cases (45.45%)were localized to the proximal stomach and 30 out of 52 cases (57.69%)were localized to the distal stomach.
  • 52.63 % of the non-mucinous type of gastric adenocarcinoma showed positive p53 immunoreactivity.
  • The mutation is more marked in the poorly differentiated gastric adenocarcinoma.
  • The antral, pylorus,and the prepyloric parts of the stomach( the distal stomach) are more prone for mutated p53 induced adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Saponara M, Di Battista M, Lolli C, Derenzini E, Pantaleo MA, Santini D, Ceccarelli C, Catena F, Nannini M, Maleddu A, Biasco G: Evaluation of Ki-67 in gastrointestinal stromal tumor (GIST). J Clin Oncol; 2009 May 20;27(15_suppl):e21510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of Ki-67 in gastrointestinal stromal tumor (GIST).
  • The two canonical parameters used for the prediction of GISTs' prognosis are tumor size and mitotic index.
  • Twenty-six cases arose from stomach and 15 from small bowel.
  • The expression of this cell-cycle related protein was correlated with tumor site (stomach; any other site), dimensions (<5 cm; >=5cm), mitotic index (<=5/50 HPFs; >5/50 HPFs), standard risk groups (low; intermediate-high) and disease free survival (DFS).
  • RESULTS: Ki-67 over-expression was positively correlated with tumor size >=5cm (p= 0.035).
  • Lower levels of Ki-67 expression have been observed in gastric GISTs compared to any other site (29 cases with Ki-67 <=10% of which 21 gastric and 8 in other sites), even if these values were not statistically significant (p = 0.527).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963442.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Di Battista M, Saponara M, Pantaleo MA, Catena F, Santini D, Lolli C, Di Scioscio V, Astorino M, Maleddu A, Nannini M, Biasco G: Microscopic margins of resection in gastrointestinal stromal tumor (GIST): An analysis of 122 patients. J Clin Oncol; 2009 May 20;27(15_suppl):10554

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic margins of resection in gastrointestinal stromal tumor (GIST): An analysis of 122 patients.
  • The prognosis is strongly correlated with both tumor size and mitotic index.
  • The most common sites of tumor origin were the stomach (54.9%) and the small bowel (36.9%).
  • Sites of tumor metastasis were liver (18.2%), peritoneum (36.4%) or both (19.3%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963950.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Aggarwal S, Prakhar P, Kohli S, Negi A, Jauhari M, Bhalla S: Retrospective analysis and chemotherapy results in extra-nodal NHL patients in a large super-speciality hospital in North India. J Clin Oncol; 2009 May 20;27(15_suppl):e19566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Out of 77 extra-nodal cases, 31(20%) were GIT NHL (Stomach -16, Colon-8, Ileum-4, and Duodenum-3) and out of the rest 46 extra-nodal cases the site of origin was - head & neck-14, skin n soft tissues -8, primary CNS-6, testicular-4, para-spinal- 3, breast mass-3, perinephric-2, bones-2 and 1 each in cervix, lung mass, liver and cervical plexus.
  • No surgery was performed in patients with stomach lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961061.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Al-Sakaff N, Lipatov O, See C, Rueschoff J, Van Cutsem E: Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol; 2009 May 20;27(15_suppl):4556

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial.
  • METHODS: Advanced GC tumour samples were centrally screened by immunohistochemistry (IHC; HercepTest) and fluorescence in situ hybridisation (FISH; PharmDx) in parallel.
  • HER2-positivity rates were higher in gastro-oesophageal junction (GEJ) than stomach cancer (33.2% vs 20.9%; p<0.001) and in intestinal than diffuse/mixed cancer (32.2% vs 6.1%/20.4%; p<0.001).
  • This is reflected in above-average HER2-positivity rates in countries with the highest GEJ:stomach cancer ratios (France 0.56 [HER2 positivity 26.9%]; Germany 0.53 [23.7%]; UK 0.33 [25.8%]) and intestinal:diffuse cancer ratios (UK 3.4 [HER2 positivity 25.8%]; Australia 2.6 [32.8%]; Japan 2.8 [27.8%]).
  • Variations in tumour location and type mostly explain the difference in HER2-positivity rates between countries.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963029.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Tisman G, Kutik SJ, Khan YA: Chemotherapy-induced suppression of serum holotranscobalamin. J Clin Oncol; 2009 May 20;27(15_suppl):e20639

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20639 Purpose: Chemotherapy-induced damage to the stomach and small intestine may inhibit the absorption of vitamin B12.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961573.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Schuhmacher C, Schlag P, Lordick F, Hohenberger W, Heise J, Haag C, Gretschel S, Mauer ME, Lutz M, Siewert JR: Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. J Clin Oncol; 2009 May 20;27(15_suppl):4510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954.
  • : 4510 Background: Combined pre- and postoperative chemotherapy improves overall survival in operable gastric cancer, although postoperative treatment is not feasible in half of the patients.
  • METHODS: Patients with locally advanced adenocarcinoma of the stomach and cardia were randomized between primary surgery or two 48-day cycles of weekly folinic acid 500 mg/m<sup>2</sup>/2h, 5-FU 2,000 mg/m<sup>2</sup>/24h plus biweekly cisplatin 50 mg/m<sup>2</sup>/1h followed by surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962708.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Song J, Choi S, Lee J, Lim S: Cytoplasmic expression of HuR and cyclooxygenase-2 expression in colon cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22161

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mRNA of cyclooxygenase-2 (Cox-2) is stabilized by HuR in several cancers, including breast, stomach, lung and brain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963663.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Cassier PA, Blesius AA, Perol D, Ray-Coquard I, Adenis A, Bui B, Bertucci F, Rios M, Le Cesne A, Blay J: Neoadjuvant imatinib in patients with locally advanced GIST in the prospective BFR14 trial. J Clin Oncol; 2009 May 20;27(15_suppl):10551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 10551 Background: The role of surgery in the management of patients with advanced gastrointestinal stromal tumors (GIST) in the era of imatinib mesylate (IM) remains unknown.
  • We sought to assess the outcome of patients with locally advanced primary GIST tumors without metastases treated with IM in the neoadjuvant setting within the prospective BFR14 phase III trial.
  • Twenty patients were PS 0 or 1, primary tumor sites were: small intestine (n=7), peritoneum (n=7), rectum (n=4), stomach (n=4), esophagus (n=2), and pelvis (n=1).
  • Nine of the 25 patients underwent surgical resection of the primary tumor after a median of 7.3 (range 3.4-12.1) months of treatment with IM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963947.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Siemerink E, Schaapveld M, Hospers GA, Mulder NH, Plukker JT: Effect of hospitals on survival and postoperative mortality of stomach cancer: A population-based study on type, referral, and volume-effect in the northeast Netherlands. J Clin Oncol; 2009 May 20;27(15_suppl):e15564

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of hospitals on survival and postoperative mortality of stomach cancer: A population-based study on type, referral, and volume-effect in the northeast Netherlands.
  • : e15564 Background: To optimize treatment results of patients with stomach cancer some institutions prompt referral to high volume hospitals with experienced surgeon's analogue to esophageal cancer.
  • METHODS: Data from all patients diagnosed with primary invasive stomach cancer from 1994-2006 were obtained from the nationwide Netherlands Cancer Registry of the north-east part of the Netherlands.
  • RESULTS: In the study period, 5243 patients were diagnosed with stomach cancer (65.6% men, 34.4% female), 44.5% underwent surgery.
  • Older age, advanced stage and proximal tumor location resulted in a lower probability of tumor resection.
  • However, patients with proximal tumors were more often referred for surgery to U (18%), especially by N-T hospitals.
  • In the non-proximal tumors the 5yrsurv was significantly better in U versus T and N-T hospitals, also after multivariate analysis.
  • CONCLUSIONS: We found highly superior survival for non-proximal tumors but not for proximal cancer in an university hospital.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962324.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Santoro J, Yorke E, Rosenzweig K, Goodman K, McNamara J, Pham H, Mageras G: Abstracts. Med Phys; 2010 Jun;37(6Part12):3090-3469

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study compares respiration-correlated kV cone beam CT (RC-kVCBCT) image guidance to standard (uncorrelated) kVCBCT for target localization in radiation treatment of thoracic and abdominal tumors.
  • METHOD AND MATERIALS: In an IRB-approved study, 9 stage II-IV non-small cell lung cancer (NSCLC) patients and 1 stage III stomach tumor patient with fiducials received a respiration-correlated planning CT (RCCT) at simulation and five RC-CBCTs during the first week of treatment.
  • The tumor in each phase of the RC-CBCT is registered to the end-expiration (EE) phase image to obtain the respiration-averaged tumor displacement relative to its EE position.
  • The RCCT and RC-CBCT images at EE are registered to obtain the tumor displacement at the EE position.
  • A vector sum of the three displacements yields the correction to the respiration-averaged tumor position.
  • CONCLUSION: Our preliminary results suggest that for many thoracic and abdominal tumors, position corrections using uncorrelated, respiration-averaged 3D imaging are consistent with those from respiration-correlated imaging; however, respiration-correlated imaging may be indicated for cases of large tumor motion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512987.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Computed tomography / Cone beam computed tomography / Image reconstruction / Lungs / Medical image reconstruction / Medical imaging / Pneumodynamics / Radiation therapy / Radiation treatment
  •  go-up   go-down


55. Pendharkar D, Salim-Ul-Zaman H: Epidemiology of cancer in Afghanistan. J Clin Oncol; 2009 May 20;27(15_suppl):e22200

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GE junction tumors were common as well.
  • The food is barbecued on wood and eaten without any spices.Similar analysis from similar altitude in Kashmir region of India, had shown very high incidence of GE junction and stomach cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964129.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Lee H, Yuh Y, Kim S: Serum lactate dehydrogenase (LDH) level as a prognostic factor for the patients with advanced gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15621

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum lactate dehydrogenase (LDH) level as a prognostic factor for the patients with advanced gastric cancer.
  • : e15621 Background: Though serum LDH level is frequently elevated in the patients with advanced gastric cancer, its clinical significance is still elusive.
  • We analyzed serum LDH level as a prognostic factor for the patients with advanced stomach cancer.
  • CONCLUSIONS: For the patients with advanced gastric cancer, high serum LDH level was related to better response to chemotherapy but shorter survival duration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962703.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Aziz SA, Banday MA, Mir MH: Comparative efficacy of adjuvant chemoradiation versus chemotherapy in surgically resected adenocarcinoma of stomach. J Clin Oncol; 2009 May 20;27(15_suppl):e15639

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative efficacy of adjuvant chemoradiation versus chemotherapy in surgically resected adenocarcinoma of stomach.
  • : e15639 Background: Outcome of carcinoma of stomach has not changed over the past decades and surgery remains the time tested primary modality of treatment.
  • The present study focuses to compare the efficacy of adjuvant chemoradiation Vs Chemotherapy alone in surgically resected adenocarcinoma of stomach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962750.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Muacevic A: Robotic radiosurgery of liver metastases of solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic radiosurgery of liver metastases of solid tumors.
  • We here report the therapeutic efficacy of a robotic radiosurgery device for local control of liver metastases of solid tumors.
  • METHODS: Patients with liver metastases not qualifying for surgery were treated with single session radiosurgery (24 Gy) using robotic image-guided real-time tumor tracking.
  • For inclusion into the radiosurgery treatment protocol, tumor volumes had to be smaller than 80cc.
  • Metastases (n=27) originated from: colon (12), rectum (2), pancreas (2), lung (1), bladder (2), malignant melanoma (1), stomach (1), cholangiocellular carcinoma (2), breast (1), ovary (1), appendix (1) and endometrium (1).
  • Median tumor volume was 21cc (range 2.2-79.3).
  • CONCLUSIONS: Robotic radiosurgery with image-guided real-time tumor tracking of liver metastases is a new and promising treatment approach for pts not eligible for surgical resection and might enhance the possibilities of multidisciplinary oncological treatment concepts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964438.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Wozniak A, Rutkowski P, Debiec-Rychter M, Siedlecki J, Michej W, Osuch C, Matlok M, Ruka W, Limon J, Polish Clinical GIST Registry: Spectrum of KIT and PDGFRA mutations in primary gastrointestinal stromal tumors: Polish Clinical GIST Registry experience. J Clin Oncol; 2009 May 20;27(15_suppl):e21504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectrum of KIT and PDGFRA mutations in primary gastrointestinal stromal tumors: Polish Clinical GIST Registry experience.
  • : e21504 Background: KIT or PDGFRA gene mutations are found in 80-90% of gastrointestinal stromal tumors (GIST).
  • The prognostic value of those mutations for the outcome in primary tumors is controversial.
  • RESULTS: KIT/PDGFRA genes mutations were found in 82% tumors: KIT was mutated in 69% and PDGFRA in 13% of tumors.
  • KIT exon 11 mutations were found at the similar rates in tumors with gastric and non-gastric localization (53.9% vs. 46.1% respectively) while KIT exon 9 duplications were more often observed in non-gastric GISTs (86.4%, p=0.00036) and PDGFRA mutations were more frequently found in tumors originated from the stomach (86.8%; p=0.00017).
  • In high risk tumors KIT exon 11 deletions were more frequently found than point mutations (p=0.017).
  • No significance of mutations for disease outcome after surgery of primary tumors was found.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963396.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Salerrno May KS, Yang GY, Iyer RV, Chandrasekhar R, Wilding G, Khushalani NI, Yendamuri SS, Gibbs JF, Fakih M: Renal atrophy secondary to chemoradiation treatment of abdominal malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):e15532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary disease sites were pancreas (61.5%), periampullary (16.1%), stomach (10.8%), gastroesophageal junction (10%), and retroperitoneum (1.5%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962316.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Pitot HC, Mould D, Maleski J, Leopold L: Analysis of a phase I pharmacokinetic (PK)/food effect study of AT-101 in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of a phase I pharmacokinetic (PK)/food effect study of AT-101 in patients with advanced solid tumors.
  • Cohort A received AT-101 (80 mg) orally on day 1 on an empty stomach (fasted) and again on day 8 with a high fat high calorie breakfast (fed), per FDA guidelines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961871.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Pandurengan RK, Strom SS, Trent J 2nd: Gastrointestinal stromal tumor associated with other primaries: A study of 154 patients. J Clin Oncol; 2009 May 20;27(15_suppl):10567

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor associated with other primaries: A study of 154 patients.
  • : 10567 Background: The objective of this study is to investigate the characteristics and survival rate of patients with Gastrointestinal Stromal Tumor (GIST) associated with other primary malignancies.
  • Multiple primaries included tumors that were not considered to be a metastasis, invasion or recurrence of GIST excluding non-melanoma skin cancer.
  • Data on gender, age at diagnosis of cancer, follow-up time after diagnosis, and death rate were collected.
  • Median age at diagnosis of GIST was 57 for patients with GIST only whereas it was 68 in patients with GIST+.
  • The stomach was the frequent site of occurrence in GIST only and GIST+.
  • The total numbers of other primaries developed before the diagnosis of GIST was higher (134) than the primaries developed after the diagnosis of GIST (53).
  • The most frequent primaries observed before the diagnosis of GIST were prostate (25), breast (12), esophagus (9), kidney (7) and melanoma (6).
  • Lung (5) and kidney (5) were the most frequent type of primaries that developed after the diagnosis of GIST.
  • The 5-yr survival was 68% for patients with GIST+ when the other primary occurred before GIST, 61% for patients with GIST+ when the other primary occurred after the diagnosis of GIST, 58% for patients with GIST only, and 49% for GIST++ patients with two or more other primaries (p=0.002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963788.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Gansler T, Comis R, Sharpe K, Tis L, Jin M, Dahlquist K, Kepner J, Hao Y, Cressman G, Naples K: Initial results of a new clinical trial matching service to increase patient participation. J Clin Oncol; 2009 May 20;27(15_suppl):e17504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the 757 individuals with available disease site and enrollment information, those with stomach cancer accounted for the most enrollments (25, 24.75% of all enrollments); followed by melanoma (12, 11.88%) and kidney, renal pelvis, bladder, ureter and urethra (also 12, 11.88%), and breast cancer (11, 10.89%).
  • Strategies for eliminating racial disparities, facilitating transportation, and increasing participation among patients with earlier stage disease and more common tumor types must be developed and implemented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963240.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Hertz P, Seruga B, Le LW, Tannock IF: Global drug development in cancer: A cross-sectional study of clinical trial registries. J Clin Oncol; 2009 May 20;27(15_suppl):2520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer sites that are major killers globally, and especially in the LDW (e.g., stomach, liver, and esophageal cancer) should receive priority for clinical research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961846.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Hirano Y, Watanabe T, Uchida T, Yoshida S, Kato H, Hosokawa O: Laparoendoscopic single site partial resection of the stomach for gastrointestinal stromal tumor. Surg Laparosc Endosc Percutan Tech; 2010 Aug;20(4):262-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoendoscopic single site partial resection of the stomach for gastrointestinal stromal tumor.
  • Preliminary experience with single-incision laparoscopic partial resection of the stomach for gastrointestinal stromal tumor (GIST) is reported.
  • The submucosal gastric tumor located in the anterior wall of the stomach was resected with 2 endoscopic staplers under the retraction of 2-mm mini-loop retractor.
  • The final pathologic diagnosis was benign GIST.
  • Laparoendoscopic single site partial resection of the stomach for GIST is feasible and a promising alternative method for scarless abdominal surgery.
  • [MeSH-major] Gastrectomy. Gastrointestinal Stromal Tumors / surgery. Laparoscopy. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20729698.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Yano H, Kimura Y, Iwazawa T, Takemoto H, Imasato M, Monden T, Okamoto S: Hand-assisted laparoscopic surgery for a large gastrointestinal stromal tumor of the stomach. Gastric Cancer; 2005;8(3):186-92
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hand-assisted laparoscopic surgery for a large gastrointestinal stromal tumor of the stomach.
  • We report two cases of large gastrointestinal stromal tumor (GIST) of the stomach that were successfully treated by hand-assisted laparoscopic surgery (HALS).
  • Two patients, a 56-year-old woman and a 60-year-old man, were admitted to our department for the treatment of a large submucosal tumor of the stomach.
  • After gastrointestinal endoscopy, ultrasonography, computed tomography, and magnetic resonance imaging, we suspected that the masses, measuring 7.0 cm and 8.0 cm in diameter, respectively, were GISTs in the stomach.
  • However, preoperatively, we could not rule out the possibility of malignant neoplasms, because they had been bleeding or gradually growing.
  • Hand-assisted laparoscopic wedge resection was safely performed for the diagnosis and treatment of the submucosal tumor of the stomach.
  • The immunohistochemical diagnosis in both patients was GIST of the stomach with intermediate-grade malignancy.
  • HALS may be a good indication for large GISTs of the stomach that are difficult to diagnose preoperatively, whether they are malignant or benign, because it is safe and minimally invasive, promoting rapid recovery.
  • [MeSH-major] Gastrointestinal Stromal Tumors / surgery. Laparoscopy. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Diagn Pathol. 1996 Nov;13(4):297-313 [8946608.001]
  • [Cites] Am J Clin Pathol. 1988 May;89(5):601-10 [3282426.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Am J Surg Pathol. 1995 Feb;19(2):207-16 [7530409.001]
  • [Cites] Acta Chir Scand. 1968;134(5):384-91 [5731276.001]
  • [Cites] Am J Clin Pathol. 1993 Oct;100(4):428-32 [8105676.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Dis Colon Rectum. 1993 Sep;36(9):858-61 [8397078.001]
  • [Cites] Hum Pathol. 1988 Jul;19(7):830-4 [3402974.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] Semin Laparosc Surg. 2001 Jun;8(2):96-103 [11441398.001]
  • [Cites] Am J Surg Pathol. 1993 Sep;17(9):887-97 [8394653.001]
  • [Cites] J Gastroenterol. 2003;38(9):896-9 [14564636.001]
  • [Cites] Cancer. 1992 Mar 15;69(6):1334-41 [1540870.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Arch Surg. 1991 Aug;126(8):985-9; discussion 989-90 [1863217.001]
  • [Cites] Surgery. 1994 Nov;116(5):842-6 [7940187.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Surg Endosc. 1994 Aug;8(8):887-9 [7992156.001]
  • [Cites] J Natl Compr Canc Netw. 2004 May;2 Suppl 1:S-1-26; quiz 27-30 [23573667.001]
  • [Cites] Surg Today. 2000;30(2):177-80 [10664344.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):728-34 [9720500.001]
  • [Cites] Dis Colon Rectum. 1995 Jul;38(7):681-5; discussion 685-6 [7607025.001]
  • [Cites] Int J Clin Oncol. 2003 Jun;8(3):180-3 [12851843.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):889-94 [15223958.001]
  • [Cites] Surg Today. 2001;31(4):346-9 [11321347.001]
  • [Cites] Ann Surg Oncol. 2002 Aug;9(7):632-6 [12167576.001]
  • (PMID = 16086122.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


67. Song SY, Noh JH, Lee SJ, Son HJ: Bronchogenic cyst of the stomach masquerading as benign stromal tumor. Pathol Int; 2005 Feb;55(2):87-91
MedlinePlus Health Information. consumer health - Stomach Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchogenic cyst of the stomach masquerading as benign stromal tumor.
  • Gastric bronchogenic cyst is an extremely rare lesion.
  • An abdominal ultrasonogram and computed tomography showed a 1.5 cm solid, homogeneous, low-density nodule in the hepatogastric ligament near the gastric lesser curvature.
  • Microscopically, the gastric subserosa showed cystic structures lined by pseudostratified ciliated columnar epithelium, seromucinous gland, connective tissue and complete layers of smooth muscle bundles.
  • The present case is the smallest reported cyst among the gastric bronchogenic cysts, and these lesions are unusually located at the lesser curvature side of the stomach.
  • Although these lesions are very rare, gastric bronchogenic cyst should be included in the differential diagnosis of gastric wall mass.
  • [MeSH-major] Bronchogenic Cyst / pathology. Gastrointestinal Stromal Tumors / diagnosis. Stomach Diseases / pathology. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Bronchogenic Cyst.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693855.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


68. Iwahashi M, Takifuji K, Ojima T, Nakamura M, Nakamori M, Nakatani Y, Ueda K, Ishida K, Naka T, Ono K, Yamaue H: Surgical management of small gastrointestinal stromal tumors of the stomach. World J Surg; 2006 Jan;30(1):28-35
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of small gastrointestinal stromal tumors of the stomach.
  • Small gastrointestinal stromal tumors (GISTs) (< 3 cm) occasionally are found in the stomach during endoscopy.
  • There is no consensus about the surgical management of these small tumors, although this clinical issue is crucial because some of the tumors show unexpected malignant behavior.
  • In this study, we evaluated the clinical management of patients with gastric GISTs who underwent surgical resection.
  • Altogether, 31 patients with gastric GISTs were examined retrospectively.
  • Surgical resection was fundamentally indicated for the patients with gastric GISTs suspected to be malignant by endoscopy or endoscopic ultrasonography (EUS).
  • The malignant grade of the GISTs was evaluated by the mitotic rate, tumor size, and MIB-1 index.
  • EUS was useful for differentiating benign from malignant GISTs; but by limiting the study to patients with small tumors (< 3 cm), the diagnostic value of EUS was not satisfactory for defining the surgical indication.
  • Tumors that were < 50 mm were successfully treated by laparoscopic surgery.
  • Of the 31 patients, 4 had a relapse of the disease, and 1 of those 4 patients had a small tumor (30 mm).
  • Surgery is indicated for gastric GISTs that are > or = 20 mm or are suspected to be malignant based on EUS findings.
  • Laparoscopic resection is feasible and is recommended as the treatment of choice for patients with tumors < 50 mm.
  • [MeSH-major] Gastrointestinal Stromal Tumors / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Aged. Endosonography. Female. Humans. Laparoscopy. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Retrospective Studies

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1989 Jan-Feb;35(1):10-5 [2646166.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):669-76 [12152168.001]
  • [Cites] Histopathology. 1999 May;34(5):416-24 [10231416.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):485-91 [12057094.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):386-92 [12654564.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):705-12 [11034250.001]
  • [Cites] World J Surg. 1991 Nov-Dec;15(6):771-6; discussion 776-7 [1767544.001]
  • [Cites] Am J Clin Pathol. 1993 Oct;100(4):428-32 [8105676.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):297-305 [9891770.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Dig Dis Sci. 2002 Oct;47(10):2247-53 [12395897.001]
  • [Cites] Scand J Gastroenterol. 1992;27(1):1-8 [1736335.001]
  • [Cites] Histopathology. 2003 Aug;43(2):118-26 [12877726.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):655-64 [12424067.001]
  • [Cites] Surg Today. 2000;30(2):177-80 [10664344.001]
  • [Cites] World J Surg. 1997 May;21(4):440-3 [9143578.001]
  • [Cites] Gastrointest Endosc. 1997 Jun;45(6):468-73 [9199902.001]
  • [Cites] Surg Endosc. 2000 Jun;14(6):524-6 [10890957.001]
  • [Cites] Surg Endosc. 1997 Mar;11(3):287-9 [9079613.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3076-81 [15131046.001]
  • [Cites] Gastric Cancer. 2003;6(1):39-48 [12673425.001]
  • [Cites] Diagn Cytopathol. 2001 Dec;25(6):343-50 [11747229.001]
  • [Cites] Hum Pathol. 1999 Oct;30(10):1213-20 [10534170.001]
  • [Cites] J Gastrointest Surg. 2005 Mar;9(3):418-29 [15749606.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):293-6 [9891769.001]
  • [Cites] Cancer. 2004 Jun 25;102(3):157-63 [15211474.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):377-89 [10199467.001]
  • [Cites] Ann Surg. 1992 Jan;215(1):68-77 [1731651.001]
  • (PMID = 16369707.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Vanwijnsberghe S, Rubay R, Descamps C, Verdebout JM, Navez B: A glomic tumour of the stomach treated by laparoscopy. Acta Chir Belg; 2006 Sep-Oct;106(5):613-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A glomic tumour of the stomach treated by laparoscopy.
  • The first gastric glomic tumour was identified in 1942 and reported with two other cases in 1951 by Key et al.
  • At present, 100 cases of glomic tumour of the stomach have been reported in the literature.
  • We report a case of benign gastric glomic tumour treated by laparoscopic surgery.
  • This type of tumour is most frequently benign but cases of malignity have been described.
  • [MeSH-major] Glomus Tumor / surgery. Laparoscopy. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168283.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


70. Lee HW, Lee JJ, Yang DH, Lee BH: A clinicopathologic study of glomus tumor of the stomach. J Clin Gastroenterol; 2006 Sep;40(8):717-20
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathologic study of glomus tumor of the stomach.
  • Glomus tumors are benign lesions and originate from modified smooth muscle cells of the glomus body.
  • These tumors are commonly observed in the dermis or subcutis, but only rarely found in the stomach.
  • Here we report a case of a 67-year-old patient in whom glomus tumor of the stomach was diagnosed after 10-day history of melena.
  • We have reviewed the 13 cases selected from literature of gastric glomus tumor in Korean, including our case.
  • The tumors typically presented with gastrointestinal bleeding or ulcerlike symptom, and 6 tumors had mucosal ulceration.
  • The tumor sizes varied from 1.2 to 3.8 cm (median 2.5 cm), and all tumors presented in antrum of stomach.
  • Microscopically, the tumors were well-circumscribed, and composed of uniform, small, round to polygonal cells.
  • The characteristics of gastric glomus tumors in Korean patients are very similar to those of Western populations.
  • Although gastric glomus tumors can be considered more likely benign, a small possibility of malignant behavior cannot be ruled out.
  • [MeSH-major] Glomus Tumor. Stomach Neoplasms
  • [MeSH-minor] Adult. Aged. Female. Humans. Korea. Male. Middle Aged. Stomach / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16940885.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


71. Zissis D, Zizi-Serbetzoglou A, Glava C, Grammatoglou X, Katsamagkou E, Nikolaidou ME, Vasilakaki T: Glomus tumor of the stomach: a case report. J BUON; 2008 Oct-Dec;13(4):581-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glomus tumor of the stomach: a case report.
  • Glomus tumors are relatively uncommon benign neoplasms, most common in the skin and subcutaneous tissue, but can also occur in the viscera, most often in the stomach.
  • Preoperative diagnosis, when the tumor occurs in the stomach, seems difficult but is important, since glomus tumors of the stomach are essentially benign and amenable to conservative excision, contrary to aggressive gastric neoplasms.
  • Gastroscopy revealed a submucosal mass in the antrum of the stomach in correspondence to the lesser curvature.
  • Biopsies taken from the lesion showed morphological and immunohistochemical [positivity for alphasmooth muscle actin (alpha-SMA) and vimentin, negativity for CD34, CD117, chromogranin, synaptophysin, desmin and S-100 protein] characteristics attributable to glomus tumor.
  • Histological examination of the tumor confirmed the diagnosis of gastric glomus tumor.
  • [MeSH-major] Glomus Tumor / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145686.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


72. Hata Y, Ishigami S, Natsugoe S, Nakajo A, Okumura H, Miyazono F, Matsumoto M, Hokita S, Aikou T: P53 and MIB-1 expression in gastrointestinal stromal tumor (GIST) of the stomach. Hepatogastroenterology; 2006 Jul-Aug;53(70):613-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53 and MIB-1 expression in gastrointestinal stromal tumor (GIST) of the stomach.
  • BACKGROUND/AIMS: Routine clinical approaches for evaluating the risk of recurrence in patients with gastrointestinal stromal tumor (GIST) of the stomach have been limited.
  • METHODOLOGY: We enrolled 31 gastric GIST patients who underwent gastrectomy at Kagoshima University Hospital.
  • Patients were classified into two groups based on mitosis and tumor diameter. p53 and MIB-1 expression in the primary tumor were detected immunohistochemically.
  • RESULTS: The patients were classified as having a malignant GIST (20 cases), a benign GIST (11 cases).
  • The MIB-1 LI for malignant GISTs was 6.3 +/- 6.4%, which was significantly higher than the 3.2 +/- 2.5% observed for benign GISTs (p < 0.01).
  • Especially, p53 expression of the tumor may indicate patients having a high risk of recurrence.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Gastrointestinal Stromal Tumors / pathology. Ki-67 Antigen / metabolism. Stomach Neoplasms / pathology. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16995473.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


73. Kamimura H, Mochiki E, Kamiyama Y, Aihara R, Kimura H, Kuwano H: Gastrointestinal stromal tumor of the stomach: report of a case. Hepatogastroenterology; 2005 Jul-Aug;52(64):1297-300
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor of the stomach: report of a case.
  • We report herein a case of a 65-year-old woman who had a gastrointestinal stromal tumor (GIST) of the stomach.
  • Preoperative endoscopic and X-ray examinations showed a spherical submucosal tumor in the gastric fornix.
  • We resected the tumor by laparoscopic surgery, because it was detected by computed tomography (CT) and positron emission tomography (PET), and they did not detect distant metastasis.
  • Postoperative histologic examination revealed that the tumor was composed of spindle-shaped cells with elongated nuclei and showed little mitosis.
  • The tumor did not show differentiation toward smooth muscle or neural cells.
  • Pathological findings showed this tumor was probably benign.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis. Gastrointestinal Stromal Tumors / surgery. Stomach Neoplasms / diagnosis. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001681.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


74. Tavusbay C, Genç H, Haciyanli M, Gür OS, Ekinci N: [Glomus tumor of the stomach: a rare cause of upper gastrointestinal bleeding]. Ulus Travma Acil Cerrahi Derg; 2009 Jan;15(1):85-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Glomus tumor of the stomach: a rare cause of upper gastrointestinal bleeding].
  • Glomus tumors are benign soft tissue neoplasms that usually arise in the skin of the extremities; however, those tumors are sometimes located in other sites such as gastrointestinal (GIS), respiratory, and genital tracts.
  • Gastrointestinal glomus tumors are mostly located in the gastric antrum.
  • Herein, we report a case of a glomus tumor of the stomach in a 31-year-old female patient who presented with intermittent nausea, vomiting, hematemesis and melena for 2 months.
  • Immunohistochemical examination showed the glomus tumor.
  • Since the glomus tumor is essentially benign and does not need a radical surgical procedure, the most important aspect of this tumor is its histologic identification and differentiation from more common gastric lesions, especially from malignant tumors.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Glomus Tumor / complications. Soft Tissue Neoplasms / complications. Stomach Neoplasms / complications
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130345.001).
  • [ISSN] 1306-696X
  • [Journal-full-title] Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES
  • [ISO-abbreviation] Ulus Travma Acil Cerrahi Derg
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


75. Sazhin VP, Naumov IA, Klimov DE, Nuzhdikhin AV: [Laparoscopic resection of the stomach by Billroth-I technique]. Khirurgiia (Mosk); 2005;(1):21-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic resection of the stomach by Billroth-I technique].
  • Laparoscopic resection of the stomach by Billroth-I technique is described.
  • Previously different variants of laparoscopic Billroth-II resection and laparoscopy-assisted Billroth-I resection have been performed a complete variant of laparoscopic Billroth-I resection of the stomach the authors reported on Symposium of Endo-surgeons in 2004.
  • [MeSH-minor] Humans. Stomach Ulcer / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15699963.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Russia
  • [Number-of-references] 6
  •  go-up   go-down


76. Lam WW, Lee JS, Ho G: MRI: imaging of stomach. Australas Radiol; 2007 Oct;51(5):432-6
Hazardous Substances Data Bank. Water .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI: imaging of stomach.
  • The study is to determine the optimal MRI bowel preparation regime for visualization of the stomach anatomy.
  • The image quality and tolerance of different stomach distension regime were evaluated.
  • Taking into account the image quality, tolerability and adverse effects, it is concluded that water is the most desirable oral contrast for MR stomach imaging.
  • [MeSH-major] Contrast Media / administration & dosage. Magnetic Resonance Imaging / methods. Stomach / anatomy & histology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. Barium sulfate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17803794.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Contrast Media; 059QF0KO0R / Water; 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


77. Yao H, Yang Z, Li Y: [Expression of checkpoint kinase 1 and polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Oct;35(10):1080-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of checkpoint kinase 1 and polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach].
  • OBJECTIVE: To determine the expressive level of checkpoint kinase 1 (CHK1) and polo-like kinase 1 (PLK1) and to detect their clinicopathological significance in benign and malignant lesions of the stomach.
  • METHODS: Envision Tm immunohistochemistry was used to detect the expression level of CHK1 and PLK1 in conventional paraffin-embedded sections from specimens of primary foci (n=59)and metastatic foci of lymph node (n=42) of gastric cancer, peritumoral tissues (n=20), and benign lesions of the stomach (n=95).
  • RESULTS: The positive rates of CHK1 were significantly higher in gastric cancer than that in different types of benign lesions(P<0.01).
  • The positive rates of PLK1 were significantly higher in gastric cancer than that in peritumoral tissues (P<0.05) and different types of benign lesions (P<0.01), and the positive cases of PLK1 in benign lesion showed atypical hyperplasia.
  • Positive correlation was found between the expression of CHK1 and PLK1 in gastric cancer tissues (P<0.01).
  • CONCLUSION: The expression level of CHK1 and /or PLK1 might be important biological markers of kinases to reflect the carcinogenesis, progression, biological behaviors, and guide clinical auxiliary treatment of gastric cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Cell Cycle Proteins / metabolism. Protein Kinases / metabolism. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21051833.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Proto-Oncogene Proteins; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / Checkpoint kinase 1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1
  •  go-up   go-down


78. Nilsson HO, Stenram U, Ihse I, Wadstrom T: Helicobacter species ribosomal DNA in the pancreas, stomach and duodenum of pancreatic cancer patients. World J Gastroenterol; 2006 May 21;12(19):3038-43
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter species ribosomal DNA in the pancreas, stomach and duodenum of pancreatic cancer patients.
  • AIM: To determine whether gastric and enteric Helicobacter species are associated with pancreatic cancer.
  • METHODS: Patients with exocrine pancreatic cancer (n = 40), neuroendocrine cancer (n = 14), multiple endocrine neoplasia type 1 (n = 8), and chronic pancreatitis (n = 5) were studied.
  • Other benign pancreatic diseases (n = 10) and specimens of normal pancreas (n = 7) were included as controls.
  • From a subset of the pancreatic cancer patients, gastric and/or duodenal tissue as well as gallbladder and ductus choledochus tissue were analyzed.
  • Stomach and duodenum samples were investigated to analyze whether a gastric helicobacter might disseminate to the pancreas in pancreatic cancer patients.
  • RESULTS: Helicobacter DNA was detected in pancreas (tumor and/or surrounding tissue) of 75% of patients with exocrine cancer, 57% of patients with neuroendocrine cancer, 38% of patients with multiple endocrine neoplasia, and 60% of patients with chronic pancreatitis.
  • All samples from other benign pancreatic diseases and normal pancreas were negative.
  • [MeSH-major] Carcinoma, Neuroendocrine / microbiology. DNA, Ribosomal / analysis. Duodenum / chemistry. Helicobacter / genetics. Multiple Endocrine Neoplasia Type 1 / microbiology. Pancreas / chemistry. Pancreatic Neoplasms / microbiology. Stomach / chemistry

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 2002 Jul;93(7):842-7 [12149151.001]
  • [Cites] N Engl J Med. 2002 Oct 10;347(15):1175-86 [12374879.001]
  • [Cites] Cancer. 2002 Nov 1;95(9):1946-53 [12404289.001]
  • [Cites] Gut. 2002 Dec;51(6):849-52 [12427788.001]
  • [Cites] Clin Infect Dis. 2003 Feb 1;36(3):349-54 [12539077.001]
  • [Cites] J Med Microbiol. 2003 Sep;52(Pt 9):765-71 [12909652.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Nov;15(11):1171-4 [14560149.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5615-8 [14662950.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Comp Med. 2004 Apr;54(2):128-58 [15134359.001]
  • [Cites] Gut. 2004 Jun;53(6):860-4 [15138214.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):763-9; discussion 769-71 [15166955.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G315-9 [15246966.001]
  • [Cites] Helicobacter. 2004 Oct;9(5):460-8 [15361086.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] Cancer Causes Control. 1993 Jul;4(4):375-82 [8347787.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 17;86(16):1222-7 [8040890.001]
  • [Cites] Oncology. 1998 Jan-Feb;55(1):16-9 [9428370.001]
  • [Cites] Ann Surg. 1998 Jan;227(1):1-9 [9445103.001]
  • [Cites] Br Med Bull. 1998;54(1):71-8 [9604432.001]
  • [Cites] Science. 2004 Nov 5;306(5698):966-8 [15528423.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):304-12 [15685542.001]
  • [Cites] Gut. 2005 Mar;54(3):396-401 [15710989.001]
  • [Cites] Gut. 2000 Mar;46(3):410-4 [10673306.001]
  • [Cites] J Clin Microbiol. 2000 Mar;38(3):1072-6 [10698999.001]
  • [Cites] Curr Microbiol. 2000 Sep;41(3):161-6 [10915200.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1431-9 [11013355.001]
  • [Cites] Gastroenterology. 2001 Jan;120(1):323-4 [11246512.001]
  • [Cites] Cancer Invest. 2001;19(1):65-75 [11291558.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 20;93(12):937-41 [11416115.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 17;94(8):632-3 [11959898.001]
  • [Cites] Pancreatology. 2002;2(4):386-95 [12138227.001]
  • (PMID = 16718784.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Ribosomal
  • [Other-IDs] NLM/ PMC4124378
  •  go-up   go-down


79. Saini N, Gupta M: Morphometry of myenteric neurons in stomach. Nepal Med Coll J; 2007 Jun;9(2):96-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphometry of myenteric neurons in stomach.
  • The musculature of fundus, body and pyloric parts of stomach are differently disposed and they perform different functions.
  • Thus the present study was conducted to study the myenteric plexus of all parts of stomach by counting the number of collections of neurons, number of neurons in each collection, diameter and area of the neurons of the plexus.
  • The stomach walls of 1 cm in size were taken from 5 cadavers of medical post mortem cases from Postgraduate Institute of Medical Sciences and Research, Chandigarh and were processed for paraffin sections.
  • [MeSH-major] Autonomic Nervous System / anatomy & histology. Gastric Fundus / innervation. Muscle, Smooth / innervation. Myenteric Plexus / anatomy & histology. Pylorus / innervation. Stomach / innervation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899957.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


80. Menon P, Rao KL, Bhasin S, Vanitha V, Thapa BR, Lal A, Vaiphei K: Giant isolated cavernous hemangioma of the stomach. J Pediatr Surg; 2007 Apr;42(4):747-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant isolated cavernous hemangioma of the stomach.
  • Giant isolate cavernous hemangiomas of the stomach are extremely rare.
  • An eight year old boy with recurrent episodes of massive hematemesis and involvement of both the anterior and posterior walls of the stomach is presented.
  • Awareness of the lesion, a combination of endoscopy and contrast enhanced CT scan are helpful in reaching a diagnosis.
  • [MeSH-major] Hemangioma, Cavernous / diagnosis. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Surg. 2007 Sep;42(9):1634-5; author reply 1635-6 [17848268.001]
  • (PMID = 17448781.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Soybel DI: Anatomy and physiology of the stomach. Surg Clin North Am; 2005 Oct;85(5):875-94, v
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anatomy and physiology of the stomach.
  • In this article, key concepts in gastric anatomy and physiology are reviewed.
  • Attention is given to historical development of concepts of acid secretion, to the role of stomach in digestion, and to the mechanisms that protect gastric mucosa from acid and hostile luminal conditions.
  • Evolving ideas that may influence understand-ing of the physiologic consequences of emerging therapeutics, and procedures that target anatomy or function of the stomach are also reviewed.
  • [MeSH-major] Stomach / anatomy & histology. Stomach / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16139026.001).
  • [ISSN] 0039-6109
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


82. Tsukamoto T, Mizoshita T, Tatematsu M: Animal models of stomach carcinogenesis. Toxicol Pathol; 2007 Aug;35(5):636-48
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Animal models of stomach carcinogenesis.
  • Although incidences of stomach cancer have decreased over the past several decades, the disease remains an important public health problem.
  • Helicobacter pylori(H. pylori) is one of the most important factors for human stomach disorders, including neoplasia, and the H. pylori-infected and carcinogen-treated Mongolian gerbil (MG) has proven very useful for analyses of underlying processes.
  • The findings with this model support the hypothesis that intestinal metaplasia is important not as a precancerous lesion but rather as a paracancerous condition and that intestinalization of stomach cancer progresses with chronic inflammation.
  • Furthermore, dose-dependent enhancing effects of salt on stomach carcinogenesis could be demonstrated in MGs treated with MNU and H. pylori modifying surface mucous gel layer. H. pylori itself only causes chronic inflammation and acts as a promoter of stomach carcinogenesis in experimental models.
  • Based on the precise pathological diagnosis of stomach lesions such as noncancerous heterotopic proliferative glands (HPG) and adenocarcinomas, a basis for understanding mechanisms of carcinogenesis has been established on which chemoprevention can be modeled.
  • [MeSH-major] Disease Models, Animal. Stomach Neoplasms / etiology
  • [MeSH-minor] Animals. Cyclooxygenase 2 / physiology. Helicobacter Infections / complications. Helicobacter pylori. Homeodomain Proteins / physiology. Humans. Metaplasia. Precancerous Conditions / pathology. Sodium Chloride, Dietary / adverse effects. Trans-Activators / physiology. Tumor Suppressor Protein p53 / physiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17654405.001).
  • [ISSN] 0192-6233
  • [Journal-full-title] Toxicologic pathology
  • [ISO-abbreviation] Toxicol Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Sodium Chloride, Dietary; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53; 0 / pancreatic and duodenal homeobox 1 protein; EC 1.14.99.1 / Cyclooxygenase 2
  • [Number-of-references] 133
  •  go-up   go-down


83. Shimoda M, Okada Y, Hayashi Y, Hatano S, Kawakubo H, Omori T, Ishii S, Sugiura H: Primary invasive micropapillary carcinoma of the stomach. Pathol Int; 2008 Aug;58(8):513-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary invasive micropapillary carcinoma of the stomach.
  • Reported herein is the case of a 74-year-old man with an unusual gastric carcinoma that developed at the lesser curvature of the stomach.
  • The tumor consisted of small clusters of carcinoma cells surrounded by clear spaces, with histopathology similar to invasive micropapillary carcinoma (IMPC) of the breast.
  • Although IMPC has been reported in breast, urinary bladder, ureter, lung, salivary gland and colon, to the best of the authors' knowledge this is the first report of IMPC arising in the stomach.
  • Presented here are the clinicopathological features of primary IMPC of the stomach.
  • [MeSH-major] Carcinoma, Papillary / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Cadherins / analysis. Disease-Free Survival. Down-Regulation. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705772.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


84. Matevossian E, Brücher BL, Nährig J, Feußner H, Hüser N: Glomus tumor of the stomach simulating a gastrointestinal stromal tumor: a case report and review of literature. Case Rep Gastroenterol; 2008;2(1):1-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glomus tumor of the stomach simulating a gastrointestinal stromal tumor: a case report and review of literature.
  • Glomus tumor is an infrequent and in most cases benign mesenchymal neoplasia which affects subcutaneous/submucosal tissue and occurs in the gastrointestinal tract, solid organs (e.g. liver, kidney) and the extremities.
  • Visceral glomus tumor of the stomach generally presents with non-specific epigastric pain, loss of appetite and GI bleeding (melaena), often without haemodynamic instability.
  • Endosonographic appearances are generally heterogenous and poorly-reflective, hence fail to differentiate glomus tumor from other potential diagnoses.
  • Histological confirmation of the diagnosis is only possible when a fine needle biopsy is inclusive of abnormal tissue.
  • These difficulties in diagnosis mean that in many cases, only immunohistochemical analysis of surgically resected tissue can distinguish glomus tumor from several possible differentials.
  • Therefore, endoscopically-assisted laparoscopic curative wedge-resection of a lesion suspicious for glomus tumor of the upper gastrointestinal tract must be considered first-line in terms of a combined investigative and curative approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Klin Med (Mosk). 1985 Mar;63(3):110-1 [2987610.001]
  • [Cites] Mt Sinai J Med. 1987 May;54(4):344-7 [3037357.001]
  • [Cites] Vopr Onkol. 1974;20(10):104-16 [4372792.001]
  • [Cites] Pathol Int. 2001 Sep;51(9):729-34 [11696178.001]
  • [Cites] Diagn Cytopathol. 2003 Jun;28(6):316-21 [12768637.001]
  • [Cites] Cancer. 1962 Sep-Oct;15:958-71 [14008985.001]
  • [Cites] Chirurg. 2006 Jan;77(1):33-40 [16372188.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):585-91 [17414106.001]
  • [Cites] J Clin Pathol. 2007 Jul;60(7):846 [17596555.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):301-11 [11859201.001]
  • [Cites] Acta Cytol. 2002 May-Jun;46(3):560-6 [12040654.001]
  • [Cites] Gastrointest Endosc. 2004 Mar;59(3):409-15 [14997145.001]
  • (PMID = 21490829.001).
  • [ISSN] 1662-0631
  • [Journal-full-title] Case reports in gastroenterology
  • [ISO-abbreviation] Case Rep Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; GIST / Gastric glomangioblastoma / Glomus tumor
  •  go-up   go-down


85. Kuzin NM, Vetshev PS, Maĭorova IuB: [Resection of the stomach with Roux anastomosis]. Khirurgiia (Mosk); 2006;(3):4-10
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Resection of the stomach with Roux anastomosis].
  • Results of surgical treatment of patients with gastric ulcer and cancer of the stomach using resection of the stomach with Roux technique were analyzed.
  • Acid-producing and evacuatory functions of the stomach were assessed in different periods after surgery.
  • Dynamic scintigraphy provided evaluation of indices of duodenogastric reflux and state of gastric mucous barrier after various types of surgeries.
  • It is concluded that Roux resection of the stomach is not inferior to Bilrot-I resection by functional results, but it has advantages by quality life and rate of operated stomach diseases compared with Bilrot-I and Bilrot-II techniques.
  • [MeSH-major] Duodenum / surgery. Gastrectomy / methods. Stomach / surgery. Stomach Neoplasms / surgery. Stomach Ulcer / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710233.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


86. Gockel I, Heintz A, Trinh TT, Domeyer M, Dahmen A, Junginger T: Laparoscopic anterior semifundoplication in patients with intrathoracic stomach. Am Surg; 2008 Jan;74(1):15-9
MedlinePlus Health Information. consumer health - Hiatal Hernia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic anterior semifundoplication in patients with intrathoracic stomach.
  • The laparoscopic management of the intrathoracic stomach is still controversial.
  • The aim of our study was to evaluate the results of laparoscopic anterior semifundoplication in patients with intrathoracic stomach.
  • Enrolled in this study are 19 patients (67.1 years of age; range, 37.5-83.7 years) with intrathoracic stomach undergoing laparoscopic anterior semifundoplication and a minimal follow up of 5 months postoperatively.
  • Including criterion was a minimum percentage of herniated intrathoracic stomach of 33 per cent.
  • The median percentage of herniated stomach in the chest was 87.5 per cent (range, 33-100%).
  • Seven patients revealed organo-axial volvulus of the stomach.
  • Although laparoscopic anterior semifundoplication yields satisfactory symptomatic results in patients with intrathoracic stomach, the incidence of failures and anatomical recurrences is higher than expected from subjective data.
  • Prospective, randomized long-term studies are essential to gain further information about the "ideal" type of laparoscopic repair in large hiatal hernia with intrathoracic stomach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18274422.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Kutateladze M, Asatiani A: [Mechanosensoric homeostatic function of the stomach]. Georgian Med News; 2005 May;(122):69-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mechanosensoric homeostatic function of the stomach].
  • Using original experimental method (partial, different extent emptying of stomach from contents in various parts of time after satiety condition--denying the food intake) the mechanosensoric, homeostatic function of the stomach was revealed while performing the chronic experiments on adult male dogs, while on puppies the ageing peculiarities of its formation was shown.
  • On polyfistuled (stomach, proximal and distal parts of duodenum) adult dogs, it was demonstrated that duodenum participates in maintenance and formation of satiety only while complex irritation by chime of the interoreceptors of gastrointestinal tract in natural succession of digestion takes place together with the sensoric processes in stomach.
  • [MeSH-major] Eating / psychology. Satiety Response / physiology. Stomach / physiology
  • [MeSH-minor] Animals. Dogs. Duodenum / physiology. Gastric Emptying. Gastrointestinal Motility. Homeostasis. Hunger / physiology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15988089.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


88. Kong F, Singh RP: Disintegration of solid foods in human stomach. J Food Sci; 2008 Jun;73(5):R67-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disintegration of solid foods in human stomach.
  • Knowledge of the disintegration of solid foods in human stomach is essential to assess the bioavailability of nutrients in the gastrointestinal (GI) tract.
  • A comprehensive review of food gastric digestion, focusing on disintegration of solid foods, is presented.
  • Stomach physiology is briefly introduced, including composition and rheological properties of gastric contents, stomach wall motility in fed/fasted states, and hydrodynamic and mechanical forces that act on the ingested food.
  • Stomach emptying rate, which controls the rate of absorption of nutrients, is highly related to the disintegration of foods.
  • Future research in this area is identified to increase our fundamental understanding of the food digestion process in the stomach as related to the food composition, material properties such as texture and microstructure, and chemical characteristics.
  • [MeSH-major] Digestion / physiology. Gastric Emptying / physiology. Stomach / metabolism

  • SciCrunch. BioNumbers: The Database of Useful Biological Numbers: Data: Value observation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18577009.001).
  • [ISSN] 1750-3841
  • [Journal-full-title] Journal of food science
  • [ISO-abbreviation] J. Food Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 137
  •  go-up   go-down


89. Mortensen MB, Fenger C: [Polyps in the stomach and duodenum]. Ugeskr Laeger; 2008 Jan 7;170(1):25-30
MedlinePlus Health Information. consumer health - Stomach Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polyps in the stomach and duodenum].
  • The most common types in the stomach are fundic gland polyps, followed by hyperplastic polyps and adenomas.
  • Gastric metaplasia, adenomas and inflammatory polyps are the most common polyps in the duodenum.
  • [MeSH-major] Duodenal Diseases / pathology. Intestinal Polyps / pathology. Polyps / pathology. Stomach Diseases / pathology
  • [MeSH-minor] Adenoma / pathology. Adenoma / therapy. Adult. Duodenal Neoplasms / pathology. Duodenal Neoplasms / therapy. Duodenoscopy. Gastroscopy. Humans. Hyperplasia

  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18208710.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 35
  •  go-up   go-down


90. Novitskaia TA, Chuprov IN, Bratanchuk SIu, Zhelbunova EA: [Malignant stromal tumor of the stomach]. Arkh Patol; 2006 Mar-Apr;68(2):44-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant stromal tumor of the stomach].
  • Gastric tumor in a male of 67 is reported.
  • Immunohistochemically and morphologically the tumor is classified as a stromal stomach neoplasm.
  • [MeSH-major] Gastric Mucosa / pathology. Gastrointestinal Stromal Tumors / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752510.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


91. Gilja OH: Ultrasound of the stomach--the EUROSON lecture 2006. Ultraschall Med; 2007 Feb;28(1):32-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasound of the stomach--the EUROSON lecture 2006.
  • The stomach is a fascinating organ.
  • The aim of this paper is to show how transabdominal ultrasonography can disclose the structural and functional abnormalities of the stomach.
  • Ultrasound of the stomach was initially performed to detect and investigate organic diseases of the gastric wall.
  • Subsequently, different methods were developed to study functional aspects of gastric pathology.
  • Ultrasound can be used to evaluate antral contractility, gastric emptying, transpyloric flow, gastric configuration, intragastric distribution of meals, gastric accommodation and strain measurement of the gastric wall.
  • Advanced methods for 3D ultrasound imaging and tissue Doppler (Strain Rate Imaging) have also been developed to study diseases of the stomach.
  • Ultrasonography still has a great potential as a clinical method, and some day our patients may receive both diagnosis and treatment in the same session.
  • [MeSH-major] Stomach / ultrasonography
  • [MeSH-minor] Eating. Gastric Emptying. Humans. Muscle Contraction. Muscle, Smooth / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304411.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 79
  •  go-up   go-down


92. Patti R, Almasio PL, Di Vita G: Granular cell tumor of stomach: a case report and review of literature. World J Gastroenterol; 2006 Jun 7;12(21):3442-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of stomach: a case report and review of literature.
  • Granular cell tumor (GCT) was described for the first time by Abrikosoff in 1926.
  • It is a relatively rare neoplasm that may occur at many sites, but most commonly in the skin or soft tissues.
  • The occurrence of GCT in the gastrointestinal tract is rare, accounting approximately for 8% of all tumors, among which the most common site is the esophagus, whereas gastric localization is very rare.
  • Gastric GCTs can be solitary or, more frequently, associated with other gastrointestinal localization.
  • Although GCTs are usually clinically and histologically benign, some malignant cases have been reported.
  • Histologically, these tumors consist of polygonal and fusiform cells disposed in compact "nests" and immunohistochemical staining for S-100 protein supports the proposed derivation from Schwann cells.
  • A correct preoperative diagnosis of this tumor can only be made in 50% of all patients and it is always based on endoscopic biopsy.
  • In this study, the authors reported a case of a 49-year-old woman with a solitary granular cell tumor of the stomach with infiltrative pattern, successfully treated with surgical resection.
  • [MeSH-major] Granular Cell Tumor / pathology. Granular Cell Tumor / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1994 Dec;89(12):2259-60 [7977263.001]
  • [Cites] Gastrointest Endosc. 1995 Feb;41(2):163-7 [7721009.001]
  • [Cites] Surg Today. 1996;26(2):119-22 [8919282.001]
  • [Cites] Gastroenterol Hepatol. 1998 Jan;21(1):26 [9503748.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):779-94 [9669341.001]
  • [Cites] Am J Gastroenterol. 1998 Oct;93(10):1993-4 [9772076.001]
  • [Cites] Arch Pathol Lab Med. 1999 Oct;123(10):967-73 [10506457.001]
  • [Cites] Arch Pathol Lab Med. 2005 May;129(5):e121-3 [15859656.001]
  • [Cites] Gut. 2000 Jan;46(1):88-92 [10601061.001]
  • [Cites] J Gastroenterol. 2000;35(8):631-4 [10955603.001]
  • [Cites] J Clin Gastroenterol. 2002 Jul;35(1):107-9 [12080245.001]
  • [Cites] J Gastroenterol. 2003;38(8):776-80 [14505133.001]
  • [Cites] Am J Gastroenterol. 1976 Apr;65(4):344-8 [180799.001]
  • [Cites] Am J Gastroenterol. 1977 Dec;68(6):595-8 [206133.001]
  • [Cites] Cancer. 1984 May 15;53(10):2104-10 [6704900.001]
  • [Cites] Am Surg. 1987 Mar;53(3):156-60 [3030172.001]
  • (PMID = 16733867.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / S100 Proteins
  • [Number-of-references] 17
  • [Other-IDs] NLM/ PMC4087881
  •  go-up   go-down


93. Nyeng P, Norgaard GA, Kobberup S, Jensen J: FGF10 signaling controls stomach morphogenesis. Dev Biol; 2007 Mar 1;303(1):295-310
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FGF10 signaling controls stomach morphogenesis.
  • Here we find that FGF10 signaling controls stomach progenitor maintenance, morphogenesis and cellular differentiation.
  • Through a characterization of the initiation of terminal differentiation of the three major gastric regions in the mouse, forestomach, corpus and antrum, we first describe the existence of a "secondary transition" event occurring in mouse stomach between E15.5 and E16.5.
  • This includes the formation of terminally differentiated squamous cells, parietal, chief and gastric endocrine cells from a pre-patterned gastric progenitor epithelium.
  • Expression analysis of both FGF and Notch signaling components suggested a role of these networks in such progenitors, which was tested through ectopically expressing FGF10 in the developing posterior stomach.
  • These data provide evidence that gastric gland specification and progenitor cell maintenance is controlled by FGF10.
  • These effects were paralleled by changes in Hes1, Shh and Wnt6 expression, suggesting that FGF10 acts in concert with multiple morphogenetic signaling systems during gastric development.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2002 Dec 2;21(23):6338-47 [12456641.001]
  • [Cites] Dev Biol. 1998 Sep 15;201(2):125-34 [9740653.001]
  • [Cites] Dev Biol. 2003 Aug 15;260(2):426-37 [12921743.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3C):2863-8 [12926124.001]
  • [Cites] Dev Dyn. 2003 Oct;228(2):185-93 [14517990.001]
  • [Cites] J Cell Biochem. 2003 Nov 1;90(4):662-91 [14587025.001]
  • [Cites] Dev Biol. 2003 Dec 15;264(2):323-38 [14651921.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1339-51 [10579975.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):36-44 [10615124.001]
  • [Cites] Development. 2000 Mar;127(5):981-8 [10662637.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1607-11 [10677506.001]
  • [Cites] Development. 2000 Sep;127(18):3913-21 [10952889.001]
  • [Cites] Dev Biol. 2001 Mar 1;231(1):47-62 [11180951.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 May;280(5):L823-38 [11290504.001]
  • [Cites] Mech Dev. 2001 Jul;105(1-2):181-4 [11429295.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):317-28 [11487541.001]
  • [Cites] Development. 2001 Dec;128(24):5109-17 [11748146.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):138-41 [9916808.001]
  • [Cites] Anat Embryol (Berl). 1999 Jun;199(6):499-508 [10350130.001]
  • [Cites] Lab Invest. 1999 Jun;79(6):639-46 [10378506.001]
  • [Cites] Differentiation. 1999 Jul;65(1):13-25 [10448710.001]
  • [Cites] Nature. 1999 Aug 26;400(6747):877-81 [10476967.001]
  • [Cites] Cell Tissue Res. 2005 Feb;319(2):267-78 [15654655.001]
  • [Cites] Genes Dev. 2005 Feb 1;19(3):311-5 [15650110.001]
  • [Cites] J Cell Biol. 2005 Mar 28;168(7):1065-76 [15781477.001]
  • [Cites] Dev Cell. 2005 Apr;8(4):611-22 [15809042.001]
  • [Cites] Development. 2005 Jun;132(12):2783-93 [15930109.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Genes Dev. 2005 Jul 15;19(14):1686-91 [16024658.001]
  • [Cites] Dev Biol. 2005 Aug 15;284(2):464-78 [16038893.001]
  • [Cites] Int J Dev Biol. 2006;50(1):17-26 [16323074.001]
  • [Cites] Genes Dev. 2006 Jan 15;20(2):253-66 [16418487.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1233-44 [16618415.001]
  • [Cites] Dev Biol. 2006 Jun 1;294(1):11-23 [16616737.001]
  • [Cites] Reprod Biol Endocrinol. 2006;4:8 [16460563.001]
  • [Cites] Endocrinology. 1999 Nov;140(11):5374-81 [10537169.001]
  • [Cites] Dev Biol. 2001 Dec 1;240(1):247-53 [11784060.001]
  • [Cites] Genes Dev. 2002 Jun 15;16(12):1488-97 [12080087.001]
  • [Cites] Development. 2002 Sep;129(17):4075-87 [12163410.001]
  • [Cites] Cancer Sci. 2003 Dec;94(12):1046-51 [14662019.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14920-5 [14657333.001]
  • [Cites] Dev Dyn. 2004 Jan;229(1):176-200 [14699589.001]
  • [Cites] Development. 2004 Aug;131(15):3627-36 [15229180.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):357-64 [15288261.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):582-94 [15300590.001]
  • [Cites] Curr Opin Genet Dev. 2004 Oct;14(5):582-90 [15380251.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Mar;130(3):135-45 [14655050.001]
  • [Cites] Toxicol Sci. 2004 Nov;82(1):341-58 [15319485.001]
  • [Cites] Anat Embryol (Berl). 1979 Oct;157(2):151-60 [517763.001]
  • [Cites] EMBO J. 1994 Mar 1;13(5):1145-56 [7907546.001]
  • [Cites] Development. 1995 Oct;121(10):3163-74 [7588051.001]
  • [Cites] J Biol Chem. 1996 Aug 2;271(31):18749-58 [8702531.001]
  • [Cites] Genes Dev. 1997 Jun 15;11(12):1583-95 [9203584.001]
  • [Cites] Curr Biol. 1997 Oct 1;7(10):801-4 [9368764.001]
  • [Cites] Development. 1997 Dec;124(23):4867-78 [9428423.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):675-89 [9516388.001]
  • [Cites] Mech Dev. 2003 Jul;120(7):801-9 [12915230.001]
  • (PMID = 17196193.001).
  • [ISSN] 0012-1606
  • [Journal-full-title] Developmental biology
  • [ISO-abbreviation] Dev. Biol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK057516; United States / NIDDK NIH HHS / DK / R01 DK070636-01A1; United States / NIDDK NIH HHS / DK / R01 DK070636; United States / NIDDK NIH HHS / DK / R01 DK070636-02; United States / NIDDK NIH HHS / DK / R01 DK 070636; United States / NIDDK NIH HHS / DK / P30 DK 57516
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fgf10 protein, mouse; 0 / Fibroblast Growth Factor 10; 0 / Hedgehog Proteins; 0 / Proto-Oncogene Proteins; 0 / Shh protein, mouse; 0 / Wnt Proteins; 0 / Wnt6 protein, mouse
  • [Other-IDs] NLM/ NIHMS19042; NLM/ PMC1864952
  •  go-up   go-down


94. Michiels A, Hubens G, Ruppert M, Balliu L, Vaneerdeweg W: Giant liposarcoma of the stomach involving the mediastinum. Acta Chir Belg; 2007 Jul-Aug;107(4):468-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant liposarcoma of the stomach involving the mediastinum.
  • A case of a liposarcoma of the stomach in a 27-year old woman is described.
  • MRI showed a giant tumour of the stomach wall, invading the surrounding organs, as well as the mediastinal region.
  • After surgical 'en-bloc' resection of the tumour, histopathologic examination yielded a diagnosis of pleiomorphic liposarcoma.
  • Nine months after surgery, she represented with a relapse of the tumour that had become inoperable.
  • Although liposarcoma is a very common soft tissue sarcoma, it is rarely seen in the stomach.
  • [MeSH-major] Liposarcoma / pathology. Mediastinum / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966553.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


95. Brenner H, Rothenbacher D, Arndt V: Epidemiology of stomach cancer. Methods Mol Biol; 2009;472:467-77
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of stomach cancer.
  • Despite a major decline in incidence and mortality over several decades, stomach cancer is still the fourth most common cancer and the second most common cause of cancer death in the world.
  • The best established risk factors for stomach cancer are Helicobacter pylori infection, the by far strongest established risk factor for distal stomach cancer, and male sex, a family history of stomach cancer, and smoking.
  • While some factors related to diet and food preservation, such as high intake of salt-preserved foods and dietary nitrite or low intake of fruit and vegetables, are likely to increase the risk of stomach cancer, the quantitative impact of many dietary factors remains uncertain, partly due to limitations of exposure assessment and control for confounding factors.
  • Future epidemiologic research should pay particular attention to differentiation of stomach cancer epidemiology by subsite, and to exploration of potential interactions between H. pylori infection, genetic, and environmental factors.
  • [MeSH-major] Stomach Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107449.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


96. Lazebnik LB, Lychkova AÉ, Khomeriki SG: [Characteristics of neurohumoral regulation of stomach in aging]. Eksp Klin Gastroenterol; 2010;(12):73-7
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of neurohumoral regulation of stomach in aging].
  • The neurohumoral regulation of the motor-secretory activity of the rabbit's and rat's stomach during aging was studied.
  • Adrenergic division's contribution in the regulation of gastric motility was lowered, cholinergic's--was slowly reduced and serotoninergic's was relatively increased.
  • Serotoninergic system enhances vagal stimulated uprise of gastric motor activity; serotoninergic system may partially compensate the age-dependent decline of the role of the cholinergic system in the regulation of gastric motility.
  • The stimulation of the vagus nerve induced serotonin secretion by EC-cells of the rat stomach.
  • [MeSH-major] Aging / physiology. Gastrointestinal Motility / physiology. Stomach / physiology. Vagus Nerve / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21560626.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


97. Fedorov VD: [Extirpation of stomach without esophagoenteroanastomosis at recurrent profuse gastric bleedings]. Khirurgiia (Mosk); 2008;(3):4-9
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extirpation of stomach without esophagoenteroanastomosis at recurrent profuse gastric bleedings].
  • Five cases of extirpation of stomach stump are analyzed.
  • These operations have been performed due to recurrent bleeding after long conservative treatment, endoscopic and surgical procedures (gastrotomy with suturing of erosions and ulcers, resection and re-resection of stomach) at the patients with severe anemia and hypoproteinemia.
  • [MeSH-major] Esophagus / surgery. Gastrointestinal Hemorrhage / surgery. Stomach / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18427523.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


98. Ohtsuka H, Kanzaki M, Imamura K, Kikkawa T, Obara T, Ishizawa M, Takahara Y, Matsumoto J: [Adult Bochdalek hernia with volvulus of the stomach]. Kyobu Geka; 2008 Sep;61(10):877-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult Bochdalek hernia with volvulus of the stomach].
  • We report a rare case of Bochdalek hernia, congenital posterolateral diaphragmatic hernia with volvulus of the stomach, in an adult A 74-year-old man was admitted to our hospital complaining of sudden abdominal pain and vomiting.
  • Upper gastrointestinal series revealed volvulus of the stomach in which the pylorus was displaced to the left.
  • [MeSH-major] Hernia, Diaphragmatic / complications. Hernia, Diaphragmatic / surgery. Stomach Volvulus / complications. Stomach Volvulus / surgery
  • [MeSH-minor] Aged. Diaphragm / surgery. Humans. Laparoscopy. Male. Stomach / surgery. Thoracoscopy. Thoracotomy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788379.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


99. Kazymov IL, Mekhdiev AG, Kurbanov FS: [Bleedings from ulcers after resection of stomach and vagotomy]. Khirurgiia (Mosk); 2008;(2):37-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bleedings from ulcers after resection of stomach and vagotomy].
  • Resection of stomach was performed in 69 (42.6%) of them, vagotomy--in 93 (57.4%).
  • Episodes of bleeding were revealed in anamnesis at 56 (81.2%) patients with peptic ulcers after stomach resection, and at 15 (16.1%)--with ulcers after vagotomy.
  • Repeated resection of gastric stump with vagotomy is indicated in great penetrating ulcers.
  • Resection of stomach is the operation of choice in majority cases of recurrent ulcers after primary vagotomy.
  • [MeSH-major] Stomach Ulcer / surgery. Vagotomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18427491.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


100. Mun SA, Larin SA, Glushkov AN, Schastlivtsev EL, Brailovskiĭ VV, Chukhrov IuS, Baĭbulatov RA: [The morbidity of stomach cancer among the workers of key industries of the Kuznetsk Basin (Kuzbas)]. Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2008 May-Jun;(3):18-21
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The morbidity of stomach cancer among the workers of key industries of the Kuznetsk Basin (Kuzbas)].
  • The data research of the retrospective analysis of the morbidity of stomach cancer in the Kirov oblast (1990-2005) is presented.
  • The forecasting of morbidity rate of stomach cancer is estimated up to 2013 considering the factual indicators of volume of output in the key industries of Kuzbas.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807870.001).
  • [ISSN] 0869-866X
  • [Journal-full-title] Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny
  • [ISO-abbreviation] Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med
  • [Language] RUS
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down






Advertisement